STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 112141

TO: Hong Liu **Location: CM1/9D08/9B01** **Art Unit: 1624** **Tu sday, January 20, 2004** **Cas Serial Number: 10/088771**	**From: Barb O'Bryen** **Location: Biotech-Chem Library** **CM1-6A05** **Phone: 308-4291** **barbara.obryen@uspto.gov**

Search Notes

Reprint of search completed 1-16-04.

```
=> fil reg; d stat que l15; fil capl; d que nos l16; fil uspatf; d que nos l17
FILE 'REGISTRY' ENTERED AT 10:37:41 ON 16 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JAN 2004  HIGHEST RN 637725-36-1
DICTIONARY FILE UPDATES:  14 JAN 2004  HIGHEST RN 637725-36-1

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

L1              STR
```



full file search done on this structure

```
REP G1=(1-4) C
VPA 14-1/2/5/6 U
NODE ATTRIBUTES:
NSPEC   IS R      AT  11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
L3          650 SEA FILE=REGISTRY SSS FUL L1
L12             STR
```



subset search done on this structure

REP G1=(1-4) C
VPA 14-1/2/5/6 U
NODE ATTRIBUTES:
NSPEC IS R AT 11
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC I Rings isolated from further fusion
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE
L15 238 SEA FILE=REGISTRY SUB=L3 SSS FUL L12

100.0% PROCESSED 650 ITERATIONS 238 ANSWERS
SEARCH TIME: 00.00.01

FILE 'CAPLUS' ENTERED AT 10:37:42 ON 16 JAN 2004

FILE COVERS 1907 - 16 Jan 2004 VOL 140 ISS 4
FILE LAST UPDATED: 15 Jan 2004 (20040115/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L1 STR
L3 650 SEA FILE=REGISTRY SSS FUL L1
L12 STR
L15 238 SEA FILE=REGISTRY SUB=L3 SSS FUL L12
L16 46 SEA FILE=CAPLUS ABB=ON L15

FILE 'USPATFULL' ENTERED AT 10:37:42 ON 16 JAN 2004

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Jan 2004 (20040115/PD)
FILE LAST UPDATED: 15 Jan 2004 (20040115/ED)
HIGHEST GRANTED PATENT NUMBER: US6678893
HIGHEST APPLICATION PUBLICATION NUMBER: US2004010831
CA INDEXING IS CURRENT THROUGH 15 Jan 2004 (20040115/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Jan 2004 (20040115/PD)

```
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2003

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.


L1             STR
L3           650 SEA FILE=REGISTRY SSS FUL L1
L12            STR
L15          238 SEA FILE=REGISTRY SUB=L3 SSS FUL L12
L17           22 SEA FILE=USPATFULL ABB=ON  L15


=> dup rem l16,l17
FILE 'CAPLUS' ENTERED AT 10:37:46 ON 16 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:37:46 ON 16 JAN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L16
PROCESSING COMPLETED FOR L17
L19            64 DUP REM L16 L17 (4 DUPLICATES REMOVED)
                  ANSWERS '1-44' FROM FILE CAPLUS
                  ANSWERS '45-64' FROM FILE USPATFULL

=> d ibib abs hitstr 1-64; fil caol; d que nos l18

L19  ANSWER 1 OF 64  CAPLUS  COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2001:459301  CAPLUS
DOCUMENT NUMBER:          135:33375
TITLE:                    Preparation of N-benzocycloalkyl-amides as inhibitors
                          or microsomal triglyceride transfer protein (MTP) and
                          apolipoprotein B (ApoB) secretion
INVENTOR(S):              Fink, Cynthia A.; Ksander, Gary M.; Kukkola, Paivi J.;
                          Wallace, Eli M.; Prashad, Mahavir
PATENT ASSIGNEE(S):       Novartis A.-G., Switz.
SOURCE:                   U.S., 101 pp.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English

                          Searched by Barb O'Bryen, STIC  308-4291
```

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6197798	B1	20010306	US 1999-357041	19990720

PRIORITY APPLN. INFO.: US 1998-120017 A 19980721
US 1998-155243P P 19980721
OTHER SOURCE(S): MARPAT 135:33375
GI



I



II

AB The title compds. (I) [wherein R2C, R3C,, R4C, R5C may be replaced by N; n = 1-3; R1 = aryl, cycloalkyl, heterocyclyl; R2-R5 = H, alkyl, halo, etc.; any two of R2-R5 at adjacent positions may be alkylenedioxy; R6 = (un)substituted NH2, acylamino, etc.] were prepd. as inhibitors of microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) secretion. For example, II was formed in a multi-step synthesis involving the coupling of (5-amidoindan-2-yl)carbamic acid tert Bu ester (3-step prepn. given) with 4'-trifluoromethyl-2-biphenylcarboxylic acid chloride (1-step prepn. given), deprotection of the amine, and addn. of benzenesulfonyl chloride. Selected invention compds. were tested for the inhibition of cellular secretion of Apo B and the lipid transfer activity of MTP and gave IC50 values in the ranges of 0.7-1.8 nM and 60-70 nM, resp. I are useful for the prevention and treatment of MTP and Apo B dependent conditions such as atherosclerosis, hypertriglyceridemia, and hypercholesteremia.

IT **321352-36-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of N-benzocycloalkyl-amides as inhibitors or microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) secretion)

RN 321352-36-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-pyridinylmethyl)amino]-

1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **256394-61-3P 256394-62-4P 256394-64-6P**
256394-65-7P 256394-79-3P 256394-85-1P
256394-90-8P 256395-00-3P 256395-01-4P
256395-06-9P 256395-19-4P 256395-21-8P
256395-26-3P 256395-41-2P 256395-93-4P
256395-98-9P 256396-06-2P 256396-08-4P
256396-20-0P 256396-28-8P 256396-66-4P
256397-13-4P 256397-32-7P 256397-38-3P
321352-23-2P 321352-25-4P 321352-26-5P
321352-33-4P 321352-34-5P 321352-37-8P
321352-39-0P 321352-40-3P 321352-41-4P
321352-42-5P 321352-43-6P 321352-46-9P
321352-48-1P 343931-16-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-benzocycloalkyl-amides as inhibitors or microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) secretion)

RN 256394-61-3 CAPLUS
CN 1-Piperazineacetamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 256394-62-4 CAPLUS
CN 4-Morpholineacetamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256394-64-6 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256394-65-7 CAPLUS
CN 4-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 256394-79-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(3-pyridinylsulfonyl)amino]-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256394-85-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(1-methyl-1H-imidazol-5-yl)sulfonyl]amino]-1H-inden-5-yl]-4'-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 256394-84-0
CMF C27 H23 F3 N4 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 256394-90-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-2,3-dihydro-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256395-00-3 CAPLUS
CN 4-Morpholinecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256395-01-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256395-06-9 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 256395-19-4 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-(2-pyridinyl)ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 256395-18-3
CMF C31 H26 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 256395-21-8 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-pyridinylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 256395-20-7
CMF C30 H24 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 256395-26-3 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester

(9CI) (CA INDEX NAME)



RN 256395-41-2 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)



RN 256395-93-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[2,3-dihydro-5-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)



RN 256395-98-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(3-pyridinylsulfonyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 256396-06-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(8-quinolinylsulfonyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256396-08-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(8-quinolinylsulfonyl)amino]-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256396-20-0 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256396-28-8 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256396-66-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[3-methyl-2-(3-thienyl)benzoyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256397-13-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(2S)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 256397-32-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2S)-2,3-dihydro-2-[(3-pyridinylsulfonyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 256397-38-3 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321352-23-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-,

monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 321352-25-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(1H-imidazol-2-ylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-26-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(1H-imidazol-2-ylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 321352-33-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-34-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-4-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-37-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(4-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-39-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(6-methyl-2-pyridinyl)methyl]amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-40-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-quinolinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-41-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(1-methyl-1H-imidazol-2-yl)methyl]amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-42-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-thiazolylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-43-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(3-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-46-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 6-methyl-N-[6,7,8,9-tetrahydro-7-[(2-pyridinylmethyl)amino]-5H-benzocyclohepten-2-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-48-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[methyl(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 343931-16-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2S)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 1993:22788 CAPLUS
DOCUMENT NUMBER: 118:22788
TITLE: Preparation of bisimide from diamine, carbon monoxide,

and haloaryl-substituted imide of Nadic acid

INVENTOR(S): Turner, S. Richard; Perry, Robert J.; Blevins, Richard W.

PATENT ASSIGNEE(S): Eastman Kodak Co., USA

SOURCE: U.S., 6 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5149824	A	19920922	US 1991-724269	19910701
CA 2071749	AA	19930102	CA 1992-2071749	19920622
JP 08027111	A2	19960130	JP 1992-170480	19920629
EP 521466	A1	19930107	EP 1992-111084	19920630
R: DE, FR, GB				

PRIORITY APPLN. INFO.: US 1991-724269 19910701

OTHER SOURCE(S): MARPAT 118:22788

GI



I

AB Compds. I (R = H; alkyl, alkoxy, etc.; Z = divalent arom. group), useful in the prepn. of addn. polyimides with good heat resistance, are prepd. by the reaction of an N-(haloaryl) deriv. of the imide of Nadic acid with CO and a primary diamine in the presence of a base and a Pd catalyst. Reacting the N-(4-iodophenyl) deriv. of the imide of Nadic acid with CO and 4,4'-oxydianiline in AcNMe2 in the presence of Ph3P, bis(triphenylphosphine)palladium chloride and a base gave I (R = H; Z = p-C6H4O-p-C6H4).

IT **145176-66-5P**
RL: PREP (Preparation)
(prepn. of, as monomer for addn. polyimides)

RN 145176-66-5 CAPLUS

CN Benzamide, 4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)-N-[4-[6-[[4-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl)benzoyl]amino]-2,3-dihydro-1,3,3-trimethyl-1H-inden-1-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L19 ANSWER 3 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 1985:496311 CAPLUS
Correction of: 1984:218962
DOCUMENT NUMBER: 103:96311
Correction of: 100:218962
TITLE: Magenta coupler with blocking group
PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58113938	A2	19830707	JP 1981-213898	19811226
JP 63022297	B4	19880511		

PRIORITY APPLN. INFO.: JP 1981-213898 19811226
GI For diagram(s), see printed CA Issue.
AB A blocked magenta coupler has a general formula of I (A = a nonmetallic atom group that forms a magenta coupler; RZCR1R2 = blocking group; Z = O, S; R1, R2 = monovalent group; R = a moiety that can couple with a developing agent and bonded to Z at its active site). The use of this coupler provides high-sensitivity and fine-grain photog. Ag halide emulsions with good storage stability and good color development can be prepd. with the use of this coupler. Thus, coupler II was added to a green-sensitive Ag(I,Br) emulsion which was coated on a triacetate support. After sensitometric exposure and normal development, the emulsion showed higer sensitivity, Dmax, and lower fog d. than a control using conventional couplers.
IT **90429-21-3**
RL: USES (Uses)
(blocked magenta coupler, for high-sensitivity fine-grained photog.

silver halide emulsions)
RN 90429-21-3 CAPLUS
CN Benzamide, N-[2-[[3-[3-[(butylsulfonyl)amino]phenyl]-6-methyl-1H-pyrazolo[5,1-c]-1,2,4-triazol-1-yl]methoxy]-2,3-dihydro-1-oxo-1H-inden-4-yl]-2-(dodecyloxy)- (9CI) (CA INDEX NAME)



L19 ANSWER 4 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 1984:122772 CAPLUS
Correction of: 1983:614173
DOCUMENT NUMBER: 100:122772
Correction of: 99:214173
TITLE: Oxoindolizine and oxoindolizinium dyes
INVENTOR(S): Fletcher, George Leland, Jr.; Bender, Steven Lee; Wadsworth, Donald Harols
PATENT ASSIGNEE(S): Eastman Kodak Co., USA
SOURCE: Eur. Pat. Appl., 129 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 68876	A1	19830105	EP 1982-303381	19820628
EP 68876	B1	19850403		
R: BE, DE, FR, GB, IT, NL				
CA 1211112	A1	19860909	CA 1982-403778	19820526
JP 58017164	A2	19830201	JP 1982-110917	19820629
JP 03042307	B4	19910626		
US 4577024	A	19860318	US 1982-412444	19820827

PRIORITY APPLN. INFO.: US 1981-278022 19810629
GI



II



III

AB The title dyes are prepd. by (1) reaction of cyclopropenones with pyridines and optionally (2) by reaction of the product from (1) with a color-forming compd. preferably in the presence of an oxidant. The dyes have a wide absorption range (visible-IR) and can be used in laser recording and reading applications and as image dyes in photothermog. and thermog. Thus, a soln. of equiv. amts. of 4-formylpyridine and 2,3-bis(4-methoxyphenyl)cyclopropenone (I) in p-dioxane was refluxed 2 h at 102.degree. under N to give cryst. II, .lambda.max 435 nm (CHCl3), in 95% yield. Similarly, I in pyridine was refluxed under N for 15 min to give a green soln. which was treated at reflux with an equiv. (based on I) of dibenzoylmethane for 60 min. Addn. of 4 equiv iodine in pyridine and heating at 90.degree. for 15 min gave III, .lambda.max 605 nm (CHCl3). Numerous other oxoindolizines and oxoindolizinium compds. are described, and several examples of their use are given.

IT **86222-18-6 86222-19-7 86222-20-0**
RL: PRP (Properties)
(dye, optical absorption max. of)

RN 86222-18-6 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1-[4-[(4-chlorobenzoyl)amino]phenyl]-2,3-dihydro-1,3,3-trimethyl-1H-inden-5-yl]-1,4-dihydro-1-oxo-4-(1-oxo-2,3-diphenyl-7(1H)-indolizinylidene)- (9CI) (CA INDEX NAME)



RN 86222-19-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-[1-[4-[(4-bromobenzoyl)amino]phenyl]-2,3-dihydro-1,3,3-trimethyl-1H-inden-5-yl]-1,4-dihydro-1-oxo-4-(1-oxo-2,3-diphenyl-7(1H)-indolizinylidene)- (9CI) (CA INDEX NAME)



RN 86222-20-0 CAPLUS
CN 2-Naphthalenecarboxamide, N-[1-[4-[(2-chlorobenzoyl)amino]phenyl]-2,3-dihydro-1,3,3-trimethyl-1H-inden-5-yl]-1,4-dihydro-1-oxo-4-(1-oxo-2,3-diphenyl-7(1H)-indolizinylidene)- (9CI) (CA INDEX NAME)



L19 ANSWER 5 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:454290 CAPLUS
DOCUMENT NUMBER: 139:36440
TITLE: Preparation of 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
INVENTOR(S): Brotherton-Pleiss, Christine E.; Madera, Ann Marie; Weikert, Robert James
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048124	A1	20030612	WO 2002-EP13220	20021125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003162780	A1	20030828	US 2002-308081	20021202
US 6627644	B2	20030930		

PRIORITY APPLN. INFO.: US 2001-336795P P 20011203
OTHER SOURCE(S): MARPAT 139:36440
GI



I



II

AB Title compds. I [A = acyl, sulfonyl; R1 = alkyl, allyl; R2-3 = H, halo, (hetero)aryl, etc.; p = 1-2] are prepd. For instance, 7-nitro-3,4-dihydro-1H-naphthalen-2-one is used to alkylate 4-(aminomethyl)piperidine-1-carboxylic acid tert-Bu ester

(1,2-dichloroethane, NaHB(OAc)3), the product alkylated with acetaldehyde (1,2-dichloroethane, NaHB(OAc)3), reduced (EtOH, H2-Pd/C) to the corresponding aniline, acylated with 4-(methanesulfonyl)benzoyl chloride (EtOAc, K2CO3), deprotected (CH2Cl2, TFA) and treated with isopropylisocyanate (CH2Cl2) to give II. Muscarinic M2/M3 inhibitory activities are detd. for selected compds. I are useful for the treatment of genitourinary disorders.

IT **540493-38-7P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-44-5P**, N-[7-[N-Ethyl-N-[[1-[morpholine-4-carbonyl]piperidin-4-yl]methyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]-4-[methanesulfonyl]benzamide **540493-45-6P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid diethylamide **540493-46-7P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid methylamide **540493-47-8P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid phenylamide **540493-48-9P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid amide **540493-49-0P**, 4-[[Ethyl[7-[4-fluorobenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-55-8P**, 4-[[Ethyl[7-[4-trifluoromethylbenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-56-9P**, 4-[[Ethyl[7-[[naphthalene-2-carbonyl]amino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-58-1P**, 4-[[Ethyl[7-[4-methoxybenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-59-2P**, 4-[[[7-[[Biphenyl-4-carbonyl]amino]-1,2,3,4-tetrahydronaphthalen-2-yl]ethylamino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-63-8P**, 4-[[[7-[4-Dimethylaminobenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]ethylamino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-64-9P**, 4-[[[7-[2,4-Difluorobenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]ethylamino]methyl]piperidine-1-carboxylic acid isopropylamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-piperidinyl alkylamine derivs. as muscarinic receptor antagonists)

RN 540493-38-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-44-5 CAPLUS

CN Benzamide, N-[7-[ethyl[[1-(4-morpholinylcarbonyl)-4-piperidinyl]methyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]-4-

(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 540493-45-6 CAPLUS
CN 1-Piperidinecarboxamide, N,N-diethyl-4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 540493-46-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 540493-47-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 540493-48-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]- (9CI) (CA

INDEX NAME)



RN 540493-49-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[7-[(4-fluorobenzoyl)amino]-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-55-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(trifluoromethyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-56-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[(2-naphthalenylcarbonyl)amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-58-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[(4-

methoxybenzoyl)amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-59-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[[7-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2-naphthalenyl]ethylamino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-63-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[[7-[[4-(dimethylamino)benzoyl]amino]-1,2,3,4-tetrahydro-2-naphthalenyl]ethylamino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-64-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[[7-[(2,4-difluorobenzoyl)amino]-1,2,3,4-tetrahydro-2-naphthalenyl]ethylamino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **540493-42-3P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-

1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester **540493-43-4P**, N-[7-[N-(Ethyl)-N-((piperidin-4-yl)methyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl]-4-[methanesulfonyl]benzamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-piperidinyl alkylamine derivs. as muscarinic receptor antagonists)

RN 540493-42-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 540493-43-4 CAPLUS
CN Benzamide, N-[7-[ethyl(4-piperidinylmethyl)amino]-5,6,7,8-tetrahydro-2-naphthalenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:434537 CAPLUS
DOCUMENT NUMBER: 139:22020
TITLE: Preparation of cyclic amides as apolipoprotein B inhibitors
INVENTOR(S): Takasugi, Hisashi; Inoue, Yoshikazu; Terasawa, Takeshi; Nagayoshi, Akira; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue, Kazumasa; Ohtsubo, Makoto; Fukumoto, Daisuke
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co., Ltd.
SOURCE: PCT Int. Appl., 297 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045921	A1	20030605	WO 2002-JP11034	20021024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002090347 A1 20021114 WO 2002-JP3529 20020409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

AU 2001-9164	A	20011128
AU 2002-443	A	20020211
TW 2002-91106855	A	20020404
WO 2002-JP3529	A	20020409
AU 2001-4722	A	20010430
AU 2002-9937	A	20020111

OTHER SOURCE(S): MARPAT 139:22020

AB The present invention relates to R1XC(O)NH-A-Z-Y-R2 (1; mostly 2-phenyl-1-cycloalkenecarboxamides and 1,1'-biphenyl-2-carboxamides) wherein R1 is (un)substituted aryl; R2 is (un)substituted aryl, (un)substituted heteroaryl, (un)substituted lower cycloalkyl, (un)substituted aryloxy, (un)substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from (un)substituted aryl or (un)substituted heteroaryl; X is bivalent residue derived from cycloalkene, naphthalene, unsatd. 5 or 6-membered heteromonocyclic group, each of which is (un)substituted, and substituted benzene; Y is -(A1)m1-(A2)m2- (A1 is -NH-, -N(R3)-, -CO-, -NHCO-, -CONH-, -COCH:CH-, -O-, -CH2O-, -CH2NHCO-, -CH2CONH or -CH(OH)-, wherein R3 is amino protective group, A2 is lower alkylene (un)substituted by aryl, and m1 and m2 = 0 or 1); and Z is direct bond or piperazine, or a salt thereof. Compds. 1 (e.g. 4'-chloro-4-methyl-N-[4-[[2-(2-pyridinyl)ethyl]amino]phenyl]-1,1'-biphenyl-2-carboxamide) inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B. For example, 4'-chloro-4-methyl-N-[4-[[2-(2-pyridinyl)ethyl]amino]phenyl]-1,1'-biphenyl-2-carboxamide exhibited 95% inhibition of Apo B secretion at 10-8 M; also, it lowered cholesterol and triglyceride levels in ddY-mice by 86 and 36%, resp. after 2 h. Example prepns. of >400 1 and 187 intermediates are included. For example, 2-isopropyl-N-[4-[[2-(2-pyridinyl)ethyl]amino]phenyl]-4-[4-(trifluoromethyl)phenyl]-5-pyrimidinecarboxamide (366 mg) was prepd. from 2-isopropyl-4-[4-(trifluoromethyl)phenyl]-5-pyrimidinecarboxylic acid (495 mg), tert-Bu 4-aminophenyl[2-(2-pyridinyl)ethyl]carbamate (470 mg) and 1-hydroxybenzotriazole hydrate (223 mg) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (315 mg) in N,N-dimethylformamide (20 mL) followed by CF3CO2H. The reactant tert-Bu 4-aminophenyl[2-(2-pyridinyl)ethyl]carbamate (15.03 g) was prepd. from tert-Bu 4-nitrophenyl[2-(2-pyridinyl)ethyl]carbamate (20.03 g) in ethanol (400 mL) and iron(III) chloride (189 mg) and active charcoal (20 g) followed by hydrazine hydrate (11.67 g).

IT **537717-17-2P**, N-[5-[[[2-[4-(Trifluoromethyl)phenyl]-1-cyclohexen-1-yl]carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-pyridinecarboxamide **537717-20-7P**, N-[5-[[[2-(4-Methylphenyl)-1-cyclohexen-1-

yl]carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-2-pyridinecarboxamide **537717-24-1P**, 2-(4-Methylphenyl)-N-[2-[(2-pyridinylacetyl)amino]-2,3-dihydro-1H-inden-5-yl]-1-cyclohexene-1-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of cyclic amide compds. as apolipoprotein B secretion inhibitors)

RN 537717-17-2 CAPLUS
CN 2-Pyridinecarboxamide, N-[2,3-dihydro-5-[[[2-[4-(trifluoromethyl)phenyl]-1-cyclohexen-1-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 537717-20-7 CAPLUS
CN 2-Pyridinecarboxamide, N-[2,3-dihydro-5-[[[2-(4-methylphenyl)-1-cyclohexen-1-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 537717-24-1 CAPLUS
CN 2-Pyridineacetamide, N-[2,3-dihydro-5-[[[2-(4-methylphenyl)-1-cyclohexen-1-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:319711 CAPLUS
DOCUMENT NUMBER: 138:338153
TITLE: Preparation of 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors
INVENTOR(S): Angell, Richard Martyn; Bamborough, Paul; Cockerill,

Searched by Barb O'Bryen, STIC 308-4291

George Stuart; Walker, Ann Louise
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032986	A1	20030424	WO 2002-EP11569	20021016

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-24936 A 20011017
OTHER SOURCE(S): MARPAT 138:338153
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted Ph; R2 = H, alkyl, (CH2)pcycloalkyl; R3 = II (wherein R4 = H, alkyl); U = Me, halo; X, Y = H, Me, halo; m = 0-4; n = 0-2; p = 0-2], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepd. E.g., 6-step synthesis of the carboxamide III, starting from 3-bromo-4-methylbenzoic acid, was given.

IT **515153-39-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamides as p38 kinase inhibitors)

RN 515153-39-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[2,3-dihydro-1-(1H-imidazol-1-yl)-1H-inden-5-yl]-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:658095 CAPLUS
DOCUMENT NUMBER: 137:201331
TITLE: Preparation of heterocyclic substituted cycloalkanecarboxamides as dopamine D3 receptor ligands
INVENTOR(S): Hendrix, James A.; Hemmerle, Horst; Urmann, Matthias; Shutske, Gregory; Strupczewski, Joseph T.; Bordeau, Kenneth J.; Jurcak, John G.; Nieduzak, Thaddeus; Jackson, Sharon Anne; Angell, Paul; Fink, David M.; Sabuco, Jean-Francois; Chiang, Yulin; Collar, Nicola
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA; Carey, James P.; Lee, George E.
SOURCE: PCT Int. Appl., 392 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066446	A1	20020829	WO 2002-US4713	20020215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1362039	A1	20031119	EP 2002-718999	20020215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-269672P P 20010216
GB 2001-17577 A 20010719
WO 2002-US4713 W 20020215
OTHER SOURCE(S): MARPAT 137:201331
GI



I



II



III



IV

AB The title compds. [I; A = CH, N; n = 1-2; when n = 1, yr = 0 or 2; when n = 2, yr = 0; g = 1-2; R3 = H, alkyl, (CH2)wPh; w = 1-3; R = (un)substituted benzothienyl, pyrazinyl, pyridyl, etc.; BCO = (CR19C20)dCO, II, III, etc.; R19, R20 = H, OH, alkyl; R21-R23 = H, alkyl; d = 3-4; R1 = H, alkyl, etc.; R2 = 3-(imidazol-1-yl)propyl, trans-4-methylcyclohexyl, trans-4-ethylcyclohexyl, etc.] that display selective binding to dopamine D3 receptors, and therefore are useful in treating central nervous system disorders such as psychotic disorders, substance dependence, substance abuse, dyskinetic disorders (e.g., Parkinson s disease, parkinsonism, neuroleptic-induced tardive dyskinesia, Gilles de la Tourette syndrome and Huntington's disease), dementia, anxiety disorders, sleep disorders, circadian rhythm disorders and mood disorders, were prepd. E.g., a multi-step synthesis of trans/trans-IV was described.. Biol. data for more than 1000 compds. I were given. The subject invention is also directed towards processes for the prepn. of the compds. I as well as methods for making and using the compds. as imaging agents for dopamine D3 receptors.

IT **452901-19-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclic substituted cycloalkanecarboxamides as dopamine D3 receptor ligands)

RN 452901-19-8 CAPLUS

CN Cyclopropanecarboxamide, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-2-[[4-[6-(trifluoromethyl)benzo[b]thien-3-yl]-1-piperazinyl]methyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:107318 CAPLUS
DOCUMENT NUMBER: 136:151163
TITLE: Preparation of indazole derivatives as JNK enzyme inhibitors
INVENTOR(S): Bhagwat, Shripad S.; Satoh, Yoshitaka; Sakata, Steven T.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 412 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010137	A2	20020207	WO 2001-US23890	20010730
WO 2002010137	C2	20030206		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002103229	A1	20020801	US 2001-910950	20010723
EP 1313711	A2	20030528	EP 2001-957332	20010730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-221799P P 20000731
WO 2001-US23890 W 20010730

OTHER SOURCE(S): MARPAT 136:151163

AB Indazole derivs., 3-R1A-5-R2-1H-indazoles (1), having activity as selective inhibitors of JNK are disclosed. In 1: A is a direct bond, -(CH2)a-, -(CH2)bCH:CH(CH2)c-, or -(CH2)bC.tplbond.C(CH2)c-; R1 is aryl, heteroaryl or heterocycle fused to Ph, each being optionally substituted with 1-4 R3; R2 is -R3, -R4, -(CH2)bC(O)R5, -(CH2)bC(:O)OR5, -(CH2)bC(O)NR5R6, -(CH2)bC(O)NR5(CH2)cC(O)R6, -(CH2)bNR5C(O)R6, -(CH2)bNR5C(O)NR6R7, -(CH2)bNR5R6, -(CH2)bOR5, -(CH2)bSOdR5 or -(CH2)bSO2NR5R6. A is 1-6; b and c are the same or different and are 0-4; d is 0-2. R3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle,

heterocyclealkyl, substituted heterocyclealkyl, -C(O)OR8, -C(O)R8, -C(O)NR8R9, -C(O)NR8OR9, -SO2NR8R9, -NR8SO2R9, -CN, -NO2, -NR8R9, -NR8C(O)R9, -NR8C(O)(CH2)bOR9, -NR8C(O)(CH2)bR9, -O(CH2)bNR5R9, or heterocycle fused to Ph. R4 is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with 1-4 R3, or R4 is halogen or hydroxy. R5, R6and R7 are the same or different and are H, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of R5, R6 and R7 are optionally substituted with 1-4 R3. R8 and R9 are the same or different and at each occurrence independently H, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R8, R9, and R8 and R9 taken together to form a heterocycle are optionally substituted with 1-4 R3 with the proviso that: when A is a direct bond and R1 is Ph, R2 is not Me, methoxy, C(O)CH3 or C(O)H; when A is a direct bond and R1 is 4-Me-Ph, R2 is not Me; when A is a direct bond and R1 is 4-F-Ph, R2 is not trifluoromethyl; when A is a direct bond or -C.tplbond.C- and R1 is Ph, R2 is not -COOEt; and when A is a direct bond and R1 is 6,7-dimethoxyisoquinolin-1-yl, R2 is not hydroxy. Such compds. have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds. Many of the claimed compds. have IC50 values .ltoreq.0.5 .mu.M in the JNK2 assay, e.g. 5-[3-(4-fluorophenyl)-1H-indazol-5-yl]-2H-1,2,3,4-tetrazole. Although the methods of prepn. are not claimed, >400 example prepns. are included.

IT **395107-61-6P**, N-(5,6,7,8-Tetrahydronaphthyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indazole derivs. as JNK enzyme inhibitors)

RN 395107-61-6 CAPLUS

CN Benzamide, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 10 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:553398 CAPLUS
DOCUMENT NUMBER: 137:116895
TITLE: Heat-developable photographic material with improved storage stability at high temperature
INVENTOR(S): Usakawa, Yasushi; Hanyu, Takeshi; Takamukai, Yasuhiko
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002207273	A2	20020726	JP 2001-3626	20010111

PRIORITY APPLN. INFO.: JP 2001-3626 20010111
OTHER SOURCE(S): MARPAT 137:116895

AB The invention relates to a heat-developable photog. film suitable for the printing plate making and medical use, wherein the photog. film contains an org. Ag salt, a reducing agent, and a compd. represented by XC(W):C(R2)R1 [X = electron withdrawing group; W = H, alkyl, alkenyl, etc.; R1 = hydroxyl, hydroxyl salt; R2 = alkyl, alkenyl, alkynyl, aryl, heterocycle; X joining together with W may form ring], and optionally a compd. represented by ZC(Y):C(R3)H [Y = electron withdrawing group; Z = H, alkyl, alkenyl, etc.; R3 = halo, oxy, thio, amino, heterocycle; Y joining together with Z may form ring], and a hydrazine compd. The photog. film shows improved high temp. storage stability (or preventing sensitivity decrease as well as fog increase).

IT **443130-40-3**
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(fog inhibitor in heat-developable photog. film for improving storage stability at high temp.)

RN 443130-40-3 CAPLUS
CN Benzamide, N-[2,3-dihydro-2-(hydroxymethylene)-1,3-dioxo-1H-inden-5-yl]-4-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)- (9CI) (CA INDEX NAME)



L19 ANSWER 11 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:868428 CAPLUS
DOCUMENT NUMBER: 136:6017
TITLE: Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
INVENTOR(S): Madera, Ann Marie; Stabler, Russell Stephen; Weikert, Robert James
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090082	A1	20011129	WO 2001-EP5631	20010517

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1289964	A1	20030312	EP 2001-933980		20010517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001011019	A	20030617	BR 2001-11019		20010517
JP 2003534331	T2	20031118	JP 2001-586271		20010517
US 2002004494	A1	20020110	US 2001-862522		20010522
US 6500822	B2	20021231			
US 2003109524	A1	20030612	US 2002-289055		20021106
US 6645958	B2	20031111			
NO 2002005641	A	20021217	NO 2002-5641		20021122
PRIORITY APPLN. INFO.:			US 2000-207483P	P	20000525
			US 2001-267617P	P	20010209
			WO 2001-EP5631	W	20010517
			US 2001-862522	A3	20010522

OTHER SOURCE(S): MARPAT 136:6017
GI



I



II

AB Title compds. such as I and II were prepd. Thus, I was prepd. in two steps from 3,4-dihydro-7-methoxy-2(1H)-naphthalenone and PrNH2. Muscarinic inhibitory activities (expressed as pKi values) of I were 8.20 (m2), 7.56 (m3), 6.30 (m5).

IT **375371-12-3P 375371-49-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1-aminoalkyl-lactams and their use as muscarinic receptor antagonists)

RN 375371-12-3 CAPLUS

CN Benzamide, N-[2-[ethyl[4-(hexahydro-7-oxo-1H-1,4-diazepin-1-yl)butyl]amino]-2,3-dihydro-1H-inden-5-yl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 375371-49-6 CAPLUS

CN Cyclopropanecarboxamide, N-[7-[[4-(hexahydro-7-oxo-1H-1,4-diazepin-1-yl)butyl]propylamino]-5,6,7,8-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 12 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:780861 CAPLUS
DOCUMENT NUMBER: 135:303895
TITLE: Preparation of imidazolyl-substituted 3,4-dihydro-2H-naphthalen-1-ones as Ras farnesyl transferase inhibitors
INVENTOR(S): Leonard, Daniele Marie; Repine, Joseph Thomas; Rewcastle, Gordon William
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079179	A2	20011025	WO 2001-US12433	20010417
WO 2001079179	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2001010074	A	20021231	BR 2001-10074	20010417
EP 1276724	A2	20030122	EP 2001-925049	20010417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531142	T2	20031021	JP 2001-576780	20010417
US 2003232790	A1	20031218	US 2002-257128	20021008

PRIORITY APPLN. INFO.: US 2000-197483P P 20000417
WO 2001-US12433 W 20010417

OTHER SOURCE(S): MARPAT 135:303895
GI



I



II

AB The title compds. I [wherein Ra, Rb, and Rc = independently H, alkyl, alkenyl, or (un)substituted (hetero)aryl or (hetero)arylalkyl; R1 and R2 = independently H, alkyl, alkenyl, or (un)substituted (hetero)aryl or (hetero)arylalkyl; and R1 and R2 may be attached through a linker or through an alkyl optionally interrupted by a linker, wherein said linker = NHCO, CONH, CO2, S, SO, SO2, O, or NRc; Y = NRc, O, CHRc, or S; n = 0, 2, or 3 with provisos; R3 = (un)substituted aryl, heteroarylalkyl, or arylalkyl; and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] were prepd. and formulated as farnesyl transferase enzyme inhibitors. For example, 4-cyanomethyl-1H-imidazole was N-protected with di-tert-Bu dicarbonate (27%) and coupled with 4-methoxy-3-methylbenzyl alc. to give [3-(4-methoxy-3-methylbenzyl)-3H-imidazol-4-yl]acetonitrile (41%). Oxidn. with 2N NaOH (97%), followed by esterification with EtOH (93%), redn. using LiAlH4 (80%), and condensation with 6-hydroxytetralone and TFA workup (43%), afforded II (6% overall yield). The latter inhibited Ras farnesyl transferase in a HEPES/K3PO4 buffer with IC50 of 0.022 .mu.M. I are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis (no data).

IT **367267-19-4P 367267-35-4P**, N-[2-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-oxo-5,6,7,8-tetrahydronaphthalene-1-yl]benzamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and formulation of imidazolyl-substituted dihydronaphthalenones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases)

RN 367267-19-4 CAPLUS

CN Benzamide, N-[5,6,7,8-tetrahydro-5-oxo-2-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 367267-35-4 CAPLUS
CN Benzamide, N-[5,6,7,8-tetrahydro-5-oxo-2-[2-[5-(phenylmethyl)-1H-imidazol-1-yl]ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 13 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:545674 CAPLUS
DOCUMENT NUMBER: 135:137516
TITLE: Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases
INVENTOR(S): Bender, Steven Lee; Bhumralkar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith Gail; Nambu, Mitchell David; Palmer, Cynthia Louise; Peng, Zhengwei; Varney, Michael David; Jia, Lei
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053274	A1	20010726	WO 2001-US1723	20010119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002103203	A1	20020801	US 2001-764306	20010119
US 6635641	B2	20031021		
EP 1252146	A1	20021030	EP 2001-906592	20010119

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001008025	A	20021105	BR 2001-8025		20010119
JP 2003529558	T2	20031007	JP 2001-553276		20010119
PRIORITY APPLN. INFO.:			US 2000-177059P	P	20000121
			WO 2001-US1723	W	20010119

OTHER SOURCE(S): MARPAT 135:137516
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH2, O, S, NH; Y = CH2, O, S, provided at least one of X and Y = CH2 or X and Y form a cyclopropyl ring; R2-3 = H, Me, halo, CF3, CN; R4 = CONHR5, NHCOR6; where R5 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R6 = (un)substituted aryl, heteroaryl, cycloalkyl, etc] are prepd. Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptobenzoic acid was treated with .alpha.-chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminoquinoline to give II. II was converted to a .beta.-thiono-ketone with thioacetanilide/n-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 .mu.M and had Ki = 2.21 nM for VEGF-R2.DELTA.50. Treatment of cancer as well as other disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.

IT **351317-89-0P 351318-14-4P 351318-72-4P 351318-82-6P 351319-54-5P 351319-92-1P 351320-69-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of heteroarylbenzamides used for inhibiting protein kinases)

RN 351317-89-0 CAPLUS
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]- (9CI) (CA INDEX NAME)



RN 351318-14-4 CAPLUS
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(pyrazinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 351318-72-4 CAPLUS
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(1H-1,2,4-triazol-3-ylthio)methyl]- (9CI) (CA INDEX NAME)



RN 351318-82-6 CAPLUS
CN Benzamide, 3-[[(5-amino-1H-1,2,4-triazol-3-yl)thio]methyl]-N-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)



RN 351319-54-5 CAPLUS
CN Benzamide, 3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 351319-92-1 CAPLUS
CN Benzamide, 3-[(pyrazinylthio)methyl]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 351320-69-9 CAPLUS
CN Benzamide, 3-(4-isoquinolinylmethoxy)-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 14 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:545662 CAPLUS
DOCUMENT NUMBER: 135:137522
TITLE: Preparation of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion
INVENTOR(S): Ksander, Gary Michael
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053260	A1	20010726	WO 2001-EP439	20010116

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1259484	A1	20021127	EP 2001-909632	20010116
JP 2003520270	T2	20030702	JP 2001-553264	20010116
US 2003109700	A1	20030612	US 2002-181006	20020711

PRIORITY APPLN. INFO.: US 2000-483971 A 20000118
WO 2001-EP439 W 20010116

OTHER SOURCE(S): MARPAT 135:137522
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R2C, R3C, R4C or R5C may be replaced by N; n = 1-3; R1 = aryl, heteroaryl, (aryl or heteroaryl)alkoxy; R2-R5 = H, alkyl, alkoxy, halo, CF3, CN; R6 = II, III (wherein m = 1-3; R7 = H, alkyl, (aryl or heteroaryl)alkyl, etc.; W = O, S, NR8; R8 = H, alkyl, aryl, etc.)] which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (apoB) secretion, were prepd. and formulated. Thus, refluxing (R)-N-(2-aminoindan-5-yl)-6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide with N,N-bis(2-chloroethyl)carbamic acid Me ester in diisopropylamine afforded the carboxamide IV which showed IC50 of about 2 nM in the apo B assay an IC50 of about 40 nM in the MTP assay.

IT **351414-67-0P 351414-83-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion)

RN 351414-67-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-83-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **351414-68-1P 351414-69-2P 351414-70-5P**
351414-71-6P 351414-72-7P 351414-73-8P
351414-74-9P 351414-75-0P 351414-76-1P
351414-77-2P 351414-78-3P 351414-79-4P
351414-80-7P 351414-81-8P 351414-82-9P
351414-84-1P 351414-85-2P 351414-86-3P
351414-87-4P 351414-88-5P 351414-89-6P
351414-90-9P 351414-91-0P 351414-92-1P
351414-93-2P 351414-94-3P 351414-95-4P
351414-96-5P 351414-97-6P 351414-98-7P
351414-99-8P 351415-00-4P 351415-01-5P
351415-02-6P 351415-03-7P 351415-04-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion)

RN 351414-68-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-phenyl-1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-69-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-methyl-1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-70-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(phenylmethyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-71-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[[[4',6-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-72-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-73-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-morpholinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-74-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-morpholinyl)-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-75-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-76-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-methoxy-1-piperidinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-77-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2,3-dihydro-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-78-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-methyl-1-piperidinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-79-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[[(4'-fluoro-6-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-80-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-81-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(2S)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 351414-82-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-84-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(1-piperazinyl)-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-85-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-(1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-86-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(1-oxobutyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-87-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(4-acetyl-1-piperazinyl)-2,3-dihydro-1H-inden-5-yl]-4',6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-88-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-89-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(methylsulfonyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-90-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(4-pyridinylcarbonyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-91-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(methoxyacetyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-92-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 351414-93-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(4-benzoyl-1-piperazinyl)-2,3-dihydro-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-94-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA

INDEX NAME)



RN 351414-95-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(hydroxyacetyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-96-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(2-pyridinylmethyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-97-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(2-pyridinyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-98-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(4-pyridinyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-99-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[3-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]benzoyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-00-4 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[[(4'-fluoro-6-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-01-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-02-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-03-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351415-04-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



IT **351415-07-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion)
RN 351415-07-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 15 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:228848 CAPLUS

DOCUMENT NUMBER: 134:266103
TITLE: Preparation of N-tetrahydronaphthalenyl carboxamides as melanin concentrating hormone antagonists
INVENTOR(S): Kato, Kaneyoshi; Terauchi, Jun; Mori, Masaaki; Suzuki, Nobuhiro; Shimomura, Yukio; Takekawa, Shiro; Ishihara, Yuji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021577	A2	20010329	WO 2000-JP6375	20000919
WO 2001021577	A3	20011004		
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1218336	A2	20020703	EP 2000-961075	20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2002003370	A2	20020109	JP 2000-290357	20000920

PRIORITY APPLN. INFO.:
JP 1999-266298 A 19990920
JP 1999-357889 A 19991216
JP 2000-126272 A 20000420
WO 2000-JP6375 W 20000919

OTHER SOURCE(S): MARPAT 134:266103
GI



I



II

AB The title compds. [I; Ar1 = (un)substituted cyclic group; X = a spacer having a main chain of 1-6 atoms; Y = a bond, a spacer having a main chain of 1-6 atoms; Ar = (un)substituted monocyclic arom. ring which may be

condensed with a 4-8 membered non-arom. ring; R1, R2 = H, a hydrocarbon group which may have substituents; NR1R2 may form a (un)substituted nitrogen-contg. hetero ring; R2 may form a spiro ring together with Ar; R2, together with the adjacent nitrogen atom and Y, may form a (un)substituted nitrogen-contg. hetero ring] and their salts, useful as agents for preventing or treating obesity, were prepd. and formulated. Thus, reacting 6-amino-2-[(dimethylamino)methyl]tetralin with 4-(4-methoxyphenyl)benzoic acid in the presence of HOBt, WSCD, Et3N and DMAP in DMF afforded the carboxamide II which showed IC50 of 40 nM in GTPgS binding assay.

IT **331755-62-5P 331755-89-6P 331755-91-0P**
331756-09-3P 331756-12-8P 331756-13-9P
331756-14-0P 331756-15-1P 331756-16-2P
331756-22-0P 331756-24-2P 331756-25-3P
331756-26-4P 331756-29-7P 331756-31-1P
331756-32-2P 331756-61-7P 331756-62-8P
331756-63-9P 331756-64-0P 331756-65-1P
331756-70-8P 331756-81-1P 331756-82-2P
331756-84-4P 331756-85-5P 331757-02-9P
331757-03-0P 331757-05-2P 331757-07-4P
331757-12-1P 331757-13-2P 331757-14-3P
331757-15-4P 331757-68-7P 331757-72-3P
331757-73-4P 331757-74-5P 331757-79-0P
331757-90-5P 331757-94-9P 331757-95-0P
331757-98-3P 331758-01-1P 331758-03-3P
331758-18-0P 331758-19-1P 331758-20-4P
331758-21-5P 331758-22-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-tetrahydronaphthalenyl carboxamides as melanin concg. hormone antagonists)

RN 331755-62-5 CAPLUS
CN Benzamide, 4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331755-89-6 CAPLUS
CN Benzamide, N-[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



546/337
514/357

RN 331755-91-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-N-[6-[(dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]- (9CI) (CA

INDEX NAME)



548/237
514/374

RN 331756-09-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-12-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



546/205
514/319

RN 331756-13-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-piperidinylmethyl)-2-naphthalenyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 331756-14-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[5,6,7,8-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-15-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[5,6,7,8-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-16-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[5,6,7,8-tetrahydro-6-(1-piperidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-22-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



548/567
514/428

RN 331756-24-2 CAPLUS
CN Benzamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4-(4-pyridinyl)- (9CI) (CA INDEX NAME)



546 | 276.4
514 | 326

RN 331756-25-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-[(4-phenyl-1-piperidinyl)methyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-26-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-(4-morpholinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



544 | 165
514 | 258.2

RN 331756-29-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-[(4-phenyl-1-piperazinyl)methyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



544 | 393
514 | 255.03

RN 331756-31-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[5,6,7,8-tetrahydro-6-(4-morpholinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-32-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[5,6,7,8-tetrahydro-6-(4-morpholinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-61-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-62-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 331756-63-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[5,6,7,8-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-64-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-fluoro-N-[5,6,7,8-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-65-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[5,6,7,8-tetrahydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-70-8 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-2',4'-difluoro- (9CI) (CA INDEX NAME)



RN 331756-81-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-5-methyl-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-82-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-5-methyl-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-84-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[5-cyano-7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331756-85-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[5-cyano-7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-02-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-03-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-[[methyl[2-(1-piperidinyl)ethyl]amino]methyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-05-2 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[6-([1,4'-bipiperidin]-1'-ylmethyl)-7,8-dihydro-2-naphthalenyl]-4'-chloro- (9CI) (CA INDEX NAME)



546/190
514/316

RN 331757-07-4 CAPLUS
CN Benzamide, 4-bromo-N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-12-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-[(2-methyl-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)



RN 331757-13-2 CAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 331757-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, 4'-[[[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 331757-15-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-methoxy- (9CI) (CA INDEX NAME)



RN 331757-68-7 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-5-methyl-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-methoxy- (9CI) (CA INDEX NAME)



RN 331757-72-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-[2-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-73-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-[2-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 331757-74-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-6-[2-(1-pyrrolidinyl)ethyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-79-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]-4'-methoxy- (9CI) (CA INDEX NAME)



RN 331757-90-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(4-morpholinylmethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331757-94-9 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(4-morpholinylmethyl)-2-naphthalenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 331757-95-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-2'-methyl- (9CI) (CA INDEX NAME)



RN 331757-98-3 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-5-methyl-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 331758-01-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 331758-03-3 CAPLUS
CN Benzamide, N-[7,8-dihydro-6-(1-pyrrolidinylmethyl)-2-naphthalenyl]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 331758-18-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 331758-19-1 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]-4'-methyl- (9CI) (CA INDEX NAME)



RN 331758-20-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]-4'-methoxy- (9CI) (CA INDEX NAME)



RN 331758-21-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-[7,8-dihydro-5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]-4'-fluoro- (9CI) (CA INDEX NAME)



RN 331758-22-6 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-N-[7,8-dihydro-5-methyl-6-[(4-methyl-1-piperazinyl)methyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 16 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:63976 CAPLUS
DOCUMENT NUMBER: 134:115862
TITLE: Preparation of N-indanyl biphenyl-2-carboxamides as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (ApoB) secretion
INVENTOR(S): Fink, Cynthia Anne; Ksander, Gary Michael
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005767	A1	20010125	WO 2000-EP6876	20000718

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-357042 A 19990720
OTHER SOURCE(S): MARPAT 134:115862
GI



I



II

AB The title compds. [I; R2C, R3C, R4C, R5C may be replaced by N; n = 1-3; R1 = carbocyclic aryl, heteroaryl; R2-R5 = H, alkyl, alkoxy, etc.; R6 = heteroaryl, (heteroaryl)alkyl; R7 = H, alkyl, carbocyclic or heterocyclic aryl-alkyl] and their pharmaceutically acceptable salts which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (ApoB) secretion and accordingly for the treatment of MTP and Apo B dependent conditions, were prepd. and formulated. E.g., a multi-step synthesis of the amide II.HCl which showed an inhibition of 86% at 01. .mu.M in the Apo B assay and IC50 of 120 nM in the MTP assay, was given.

IT **321352-25-4P 321352-36-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of N-indanyl biphenyl-2-carboxamides as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (ApoB) secretion)

RN 321352-25-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(1H-imidazol-2-ylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-36-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **321352-23-2P 321352-24-3P 321352-26-5P**
321352-33-4P 321352-34-5P 321352-38-9P
321352-39-0P 321352-40-3P 321352-41-4P
321352-42-5P 321352-44-7P 321352-45-8P
321352-46-9P 321352-48-1P 321352-49-2P
321352-50-5P 321352-51-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-indanyl biphenyl-2-carboxamides as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (ApoB) secretion)

RN 321352-23-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 321352-24-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2S)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 321352-26-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(1H-imidazol-2-ylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 321352-33-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(1-methyl-1H-pyrrol-2-yl)methyl]amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-34-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-4-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-38-9 CAPLUS
CN 2-Naphthalenesulfonic acid, compd. with N-[2,3-dihydro-2-[(4-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 321352-37-8
CMF C30 H26 F3 N3 O



CM 2

CRN 120-18-3
CMF C10 H8 O3 S



RN 321352-39-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(6-methyl-2-pyridinyl)methyl]amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 321352-40-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-quinolinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-41-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(1-methyl-1H-imidazol-2-yl)methyl]amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-42-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-thiazolylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-44-7 CAPLUS
CN 2-Naphthalenesulfonic acid, compd. with N-[2,3-dihydro-2-[(3-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 321352-43-6
CMF C30 H26 F3 N3 O



CM 2

CRN 120-18-3
CMF C10 H8 O3 S



RN 321352-45-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-4',6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-46-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 6-methyl-N-[6,7,8,9-tetrahydro-7-[(2-pyridinylmethyl)amino]-5H-benzocyclohepten-2-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-48-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[methyl(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-49-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(2-pyridinylamino)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 321352-50-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2S)-2,3-dihydro-2-(2-pyrimidinylamino)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321352-51-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 17 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:31473 CAPLUS
DOCUMENT NUMBER: 134:100864

TITLE: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

INVENTOR(S): Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; Reich, Siegfried Heinz; Tempczyk-russell, Anna Maria; Teng, Min; Thomas, Christine; Varney, Michael David; Wallace, Michael Brennan

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 439 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001002369	A2	20010111	WO 2000-US18263	20000630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000012352	A	20020514	BR 2000-12352	20000630
EP 1218348	A2	20020703	EP 2000-943375	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503481	T2	20030128	JP 2001-507809	20000630
NZ 516676	A	20030926	NZ 2000-516676	20000630
US 6531491	B1	20030311	US 2001-983786	20011025
US 6534524	B1	20030318	US 2001-983783	20011025
NO 2001005797	A	20020301	NO 2001-5797	20011128
ZA 2001010061	A	20030206	ZA 2001-10061	20011206
BG 106380	A	20020930	BG 2002-106380	20020201

PRIORITY APPLN. INFO.:
US 1999-142130P P 19990702
US 2000-609335 B3 20000630
WO 2000-US18263 W 20000630

OTHER SOURCE(S): MARPAT 134:100864

GI



I

AB Indazole compds. I [R1 = substituted or unsubstituted aryl or heteroaryl, R3CH:CH, R3N:CH; R2 = substituted or unsubstituted aryl, heteroaryl, Y-X; R3 = substituted or unsubstituted alkyl alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = O, S, C(:CH2), CO, SO, SO2, alkylidene, NH, N(C1-C8 alkyl); X = substituted or unsubstituted aryl, heteroaryl, NH(alkyl), NH(cycloalkyl), NH(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH(alkoxy), NH(dialkylamide)] and their pharmaceutically

acceptable prodrugs, active metabolites, and salts are disclosed. The compds. modulate and/or inhibit the activity of certain protein kinases. In particular, I and pharmaceutical compns. contg. them are capable of mediating tyrosine kinase signal transduction, and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compns. contg. such compds., and to methods of treating cancer and other disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amts. of such compds. E.g., I [R1 = (E)-3,4-(MeO)2C6H3CH:CH; R2 = 4-HO-3-MeOC6H3] (II) was prepd. from 6-aminoindazole by diazotization and substitution with iodide, protection of the indazole nitrogen with 2,4,6-Me3C6H2SO2Cl, coupling of the regioisomeric mixt. with 4-(methoxymethoxy)-3-methoxybenzeneboronic acid in the presence of dichlorobis(triphenylphosphine)palladium, and deprotection of the indazole moiety and iodination at the 3-position of the indazole. Treatment of the 3-indazolyl iodide with sec-butyllithium, phenyllithium, and DMF, regioselective protection of the indazole with 2,4,6-Me3C6H2SO2Cl, olefination with 3,4-dimethoxybenzyltriphenylphosphonium bromide, deprotection of the indazole, deprotection of the methoxymethyl group, and equilibration of the double bond with iodine gave II. Biol. data on protein kinase inhibition, cell proliferation inhibition, neovascularization inhibition, and i.p. and oral bioavailability, are given.

IT **319468-45-6P 319468-46-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

RN 319468-45-6 CAPLUS
CN Benzamide, 2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319468-46-7 CAPLUS
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L19 ANSWER 18 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:843103 CAPLUS
DOCUMENT NUMBER: 136:128588
TITLE: Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors
AUTHOR(S): Ksander, Gary M.; deJesus, Reynalda; Yuan, Andrew; Fink, Cynthia; Moskal, Michael; Carlson, Eric; Kukkola, Paivi; Bilci, Natalie; Wallace, Eli; Neubert, Alan; Feldman, David; Mogelesky, Therese; Poirier, Kevin; Jeune, Michael; Steele, Ronald; Wasvery, Jong; Stephan, Zouhair; Cahill, Edna; Webb, Randy; Navarrete, Aida; Lee, Warren; Gibson, Joyce; Alexander, Natalya; Sharif, Haamid; Hospattankar, Ashok
CORPORATE SOURCE: Metabolic and Cardiovascular Diseases Research, Novartis Institute for Biomedical Research, Summit, NJ, 07901, USA
SOURCE: Journal of Medicinal Chemistry (2001), 44(26), 4677-4687
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The synthesis and biol. activities of biarylamide-substituted diaminoindanes as microsomal triglyceride transfer protein (MTP) inhibitors are described. One of the more potent compds. (I) inhibited both the secretion of apoB from Hep G2 cells and the MTP-mediated transfer of triglycerides between synthetic acceptor and donor liposomes with IC50 values of 0.7 and 70 nM, resp. In normolipidemic rats and dogs, oral

administration of I dose-dependently reduced both plasma triglycerides and total cholesterol. Moreover, in rats and dogs, I also prevented the postprandial rise in plasma triglycerides following a bolus administration of a fat load. Because MTP inhibitors decrease very low d. lipoprotein assembly in the liver, the potential for hepatic lipid accumulation was evaluated. In normolipidemic rats, hepatic cholesterol and triglyceride contents were dose-dependently increased by I. However, hepatic lipid accumulation resulted in negligible change in total liver wt. and was reversible after withdrawal of the compd.

IT **321352-24-3P 351414-80-7P 351414-81-8P 391655-10-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and structure activity of diaminoindanes as inhibitors of microsomal triglyceride transfer protein)

RN 321352-24-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2S)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 351414-80-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-81-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[(2S)-2,3-dihydro-5-[[[6-methyl-4'-

(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 391655-10-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-[(2-pyridinylmethyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 19 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:303226 CAPLUS
DOCUMENT NUMBER: 135:93901
TITLE: The use of self-organising neural networks in dye design
AUTHOR(S): Greaves, A. J.; Gasteiger, J.
CORPORATE SOURCE: Department of Colour Chemistry, University of Leeds, Leeds, LS2 9JT, UK
SOURCE: Dyes and Pigments (2001), 49(1), 51-63
CODEN: DYPIDX; ISSN: 0143-7208
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal

Searched by Barb O'Bryen, STIC 308-4291

LANGUAGE: English

AB The mapping of mol. surfaces is of particular interest to dye chemists for numerous reasons, none more so than the prediction of dye-substrate binding. Self-organizing neural networks have been used to map the hydrogen bonding and electrostatic and hydrophobic 3D mol. surface potentials of 63 anionic (Na sulfonate) water-sol. dyes. The results indicate that the hydrogen bonding potential, the mol. electrostatic potential and their combination are useful in classifying the dyes and that the hydrogen bonding potential is a useful mol. descriptor of substantivity.

IT **307354-75-2 307354-84-3**
RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)
(dye; anionic dye substantivity prediction using hydrogen bonding potential)

RN 307354-75-2 CAPLUS

CN 2,7-Naphthalenedisulfonic acid, 5-[[4-[(5-chloro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]benzoyl]amino]-3,4-dihydro-4-oxo-3-[(2-sulfophenyl)hydrazono]-, trisodium salt (9CI) (CA INDEX NAME)



RN 307354-84-3 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, 2-[[8-[[4-[(6-chloro-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)amino]benzoyl]amino]-1-oxo-3,6-disulfo-2(1H)-naphthalenylidene]hydrazino]-, tetrasodium salt (9CI) (CA INDEX NAME)



● 4 Na

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 20 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:573794 CAPLUS
DOCUMENT NUMBER: 133:177102
TITLE: Preparation of phenyl ureas and thioureas as human orexin receptor antagonists
INVENTOR(S): Coulton, Steven; Johns, Amanda; Porter, Roderick Alan
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047580	A2	20000817	WO 2000-EP1142	20000210
WO 2000047580	A3	20001221		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144409	A2	20011017	EP 2000-907553	20000210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002536447	T2	20021029	JP 2000-598500	20000210
US 6596730	B1	20030722	US 2001-913228	20011205

PRIORITY APPLN. INFO.:
GB 1999-3241 A 19990212
GB 1999-26441 A 19991108
WO 2000-EP1142 W 20000210

OTHER SOURCE(S): MARPAT 133:177102
GI



I

AB The title compds. [I; one of X and Y = N and the other = CH; Z = O, S; R1 = alkyl; alkenyl, alkoxy, etc.; R2-R6 = alkyl, alkenyl, alkoxy, etc,; an adjacent pair of R2-R6 together with the carbon atoms to which they are attached form (un)substituted carbocyclyl, heterocyclyl; R7 = alkyl, alkenyl, alkoxy, etc.; n = 0-3], useful for treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, were prepd. E.g., a multi-step synthesis of I [X = N; Y = CH; Z = O; R1, R2, R5, R6 = H; R3 = CONHCH2(cyclopropyl); R4 = OMe; R7 = Me] which showed pKb > 7.5 against human orexin-1 receptor, was given.

IT **288326-41-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of Ph ureas and thioureas as human orexin receptor antagonists)

RN 288326-41-0 CAPLUS

CN Benzamide, 2-methoxy-5-[[[(2-methyl-1,5-naphthyridin-4-yl)amino]carbonyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)-(9CI) (CA INDEX NAME)



IT **288326-42-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of Ph ureas and thioureas as human orexin receptor antagonists)

RN 288326-42-1 CAPLUS

CN Benzamide, 2-methoxy-5-[[[(2-methyl-1,5-naphthyridin-4-

yl)amino]carbonyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)-(9CI) (CA INDEX NAME)



L19 ANSWER 21 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:335388 CAPLUS
DOCUMENT NUMBER: 132:347491
TITLE: Preparation of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors
INVENTOR(S): Altmann, Karl-Heinz; Bold, Guido; Furet, Pascal; Manley, Paul William; Wood, Jeanette Marjorie; Ferrari, Stefano; Hofmann, Francesco; Mestan, Jurgen; Huth, Andreas; Kruger, Martin; Seidelmann, Dieter; Menrad, Andreas; Haberey, Martin; Thierauch, Karl-Heinz
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Schering Aktiengesellschaft
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027820	A1	20000518	WO 1999-EP8545	19991108
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2346898	AA	20000518	CA 1999-2346898	19991108
BR 9915210	A	20010724	BR 1999-15210	19991108
EP 1129075	A1	20010905	EP 1999-971802	19991108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529453	T2	20020910	JP 2000-581000	19991108
AU 758230	B2	20030320	AU 2000-13811	19991108
NZ 511339	A	20030725	NZ 1999-511339	19991108
NO 2001001894	A	20010704	NO 2001-1894	20010417
ZA 2001003290	A	20030123	ZA 2001-3290	20010423
US 2002019414	A1	20020214	US 2001-850434	20010507

US 6448277 B2 20020910
ZA 2001004673 A 20020909 ZA 2001-4673 20010607
US 2003064992 A1 20030403 US 2002-180289 20020626
PRIORITY APPLN. INFO.: GB 1998-24579 A 19981110
WO 1999-EP8545 W 19991108
US 2001-850434 A3 20010507
OTHER SOURCE(S): MARPAT 132:347491
GI



I

AB Use of title compds. I; W = O, S; X = NR8; Y = CR9R10(CH2)n, SO2; R9, R10 = H, alkyl; n = 0-3; R1 = aryl; R2 = mono- or bicyclic heteroaryl with the exception that R2 cannot = 2-phthalimidyl, and when Y = SO2 cannot represent 2,1,3-benzothiadiazol-4-yl; R3-R6 = H, substituent; R7, R8 = H, alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof, for the prepn. of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity is claimed. Thus, a mixt. of 4-pyridinecarboxaldehyde and 2-amino-N-(4-trifluoromethylphenyl)benzamide (prepn. given) in MeOH contg. HOAc was treated with NaBH3CN followed by 16 h stirring to give 2-[(4-pyridyl)methyl]amino-N-[4-(trifluoromethyl)phenyl]benzamide. Tested I inhibited Flt-1 VEGF receptor tyrosine kinase with IC50 = 0.18-0.56 .mu.M.

IT **269391-13-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-aryl(thio)anthranilic acid amides as VEGF receptor tyrosine kinase inhibitors)

RN 269391-13-1 CAPLUS

CN Benzamide, 2-[(4-pyridinylmethyl)amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 22 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:84757 CAPLUS
DOCUMENT NUMBER: 132:122391
TITLE: Preparation of N-benzocycloalkyl-amides as inhibitors or microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) secretion
INVENTOR(S): Fink, Cynthia Anne; Ksander, Gary Michael; Kukkola, Paivi Jaana; Wallace, Eli Melville
PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis-Erfindungen Verwaltungsgesellschaft Mbh
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000005201	A1	20000203	WO 1999-EP5131	19990719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338198	AA	20000203	CA 1999-2338198	19990719
AU 9951613	A1	20000214	AU 1999-51613	19990719
EP 1097129	A1	20010509	EP 1999-936567	19990719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002521360	T2	20020716	JP 2000-561158	19990719

PRIORITY APPLN. INFO.: US 1998-120017 A 19980721
WO 1999-EP5131 W 19990719

OTHER SOURCE(S): MARPAT 132:122391
GI



I



II

AB The title compds. [I; R2C, R3C,, R4C, R5C may be replaced by N; n = 1-3; R1 = aryl, cycloalkyl, heterocyclyl; R2-R5 = H, alkyl, halo, etc.; any two of R2-R5 at adjacent positions are alkylenedioxy; R6 = (un)substituted NH2, acylamino, etc.], useful as inhibitors or microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) secretion and accordingly for the prevention and treatment of MTP and Apo B dependent conditions such as atherosclerosis, hypertriglyceridemia or hypercholesteremia, were prepd. and formulated. E.g., a multi-step synthesis of II was given. Biol. data for compds. I were presented.

IT **256394-61-3P 256394-62-4P 256394-64-6P**
256394-65-7P 256394-79-3P 256394-85-1P
256394-90-8P 256395-00-3P 256395-01-4P
256395-06-9P 256395-19-4P 256395-21-8P
256395-26-3P 256395-41-2P 256395-93-4P
256395-98-9P 256396-06-2P 256396-08-4P
256396-20-0P 256396-28-8P 256396-66-4P
256397-13-4P 256397-32-7P 256397-38-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-benzocycloalkyl-amides as inhibitors or microsomal triglyceride transfer protein (MTP) and apolipoprotein B (ApoB) secretion)

RN 256394-61-3 CAPLUS

CN 1-Piperazineacetamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 256394-62-4 CAPLUS
CN 4-Morpholineacetamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256394-64-6 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256394-65-7 CAPLUS
CN 4-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 256394-79-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(3-

pyridinylsulfonyl)amino]-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256394-85-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[[(1-methyl-1H-imidazol-5-yl)sulfonyl]amino]-1H-inden-5-yl]-4'-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 256394-84-0
CMF C27 H23 F3 N4 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 256394-90-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-2,3-dihydro-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256395-00-3 CAPLUS
CN 4-Morpholinecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256395-01-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256395-06-9 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 256395-19-4 CAPLUS

CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-(2-pyridinyl)ethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 256395-18-3
CMF C31 H26 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 256395-21-8 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-pyridinylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 256395-20-7
CMF C30 H24 F3 N3 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 256395-26-3 CAPLUS
CN Carbamic acid, [2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 256395-41-2 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256395-93-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[2,3-dihydro-5-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256395-98-9 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(3-pyridinylsulfonyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 256396-06-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(8-quinolinylsulfonyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-(9CI) (CA INDEX NAME)



RN 256396-08-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[(8-quinolinylsulfonyl)amino]-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 256396-20-0 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-(9CI) (CA INDEX NAME)



RN 256396-28-8 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256396-66-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-[2,3-dihydro-5-[[3-methyl-2-(3-thienyl)benzoyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 256397-13-4 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(2S)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 256397-32-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2S)-2,3-dihydro-2-[(3-pyridinylsulfonyl)amino]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 256397-38-3 CAPLUS
CN 5-Isoxazolecarboxamide, N-[(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 23 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:780039 CAPLUS
DOCUMENT NUMBER: 134:8630
TITLE: A chemometric approach to understanding the bioelimination of anionic, water-soluble dyes by a biomass - Part 4: reactive dyes
AUTHOR(S): Churchley, J. H.; Greaves, A. J.; Hutchings, M. G.; Phillips, D. A. S.; Taylor, J. A.
CORPORATE SOURCE: Severn Trent Water plc, Coventry, CV3 6PR, UK
SOURCE: Journal of the Society of Dyers and Colourists (2000), 116(10), 323-329
CODEN: JSDCAA; ISSN: 0037-9859
PUBLISHER: Society of Dyers and Colourists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The bioelimination of a series of hydrolyzed reactive dyes of known chem. structure was detd. using a new, rapid and robust lab. method and a chemometric anal. conducted on the bioelimination results. The level of bioelimination varies from 0% to only .ltoreq.25% and the chemometric anal. indicates that if either the no. of arom. rings increases or the no. of 2-hydroxyethylsulfone groups decreases, then the bioelimination increases. To maximize the bioelimination of reactive dyes, large, planar triazine-based dyes should be used.

IT **307354-75-2 307354-84-3**
RL: POL (Pollutant); REM (Removal or disposal); OCCU (Occurrence); PROC (Process)
(chemometric approach to understanding bioelimination of anionic water-sol. reactive dyes by biomass)

RN 307354-75-2 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-[[4-[(5-chloro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)amino]benzoyl]amino]-3,4-dihydro-4-oxo-3-[(2-sulfophenyl)hydrazono]-, trisodium salt (9CI) (CA INDEX NAME)



RN 307354-84-3 CAPLUS
CN 1,5-Naphthalenedisulfonic acid, 2-[[8-[[4-[(6-chloro-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl)amino]benzoyl]amino]-1-oxo-3,6-disulfo-2(1H)-naphthalenylidene]hydrazino]-, tetrasodium salt (9CI) (CA INDEX NAME)



● 4 Na

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:487265 CAPLUS
DOCUMENT NUMBER: 131:116084
TITLE: Preparation of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as potassium channel blockers
INVENTOR(S): Gross, Michael F.; Castle, Neil A.
PATENT ASSIGNEE(S): Icagen, Inc., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9937607	A1	19990729	WO 1999-US1663	19990127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6333337	B1	20011225	US 1999-229315	19990113
ZA 9900550	A	19990726	ZA 1999-550	19990126
CA 2317457	AA	19990729	CA 1999-2317457	19990127
AU 9922419	A1	19990809	AU 1999-22419	19990127
AU 745845	B2	20020411		
EP 1051394	A1	20001115	EP 1999-902443	19990127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002501041	T2	20020115	JP 2000-528531	19990127
BR 9907236	A	20020122	BR 1999-7236	19990127
NO 2000003600	A	20000926	NO 2000-3600	20000713

PRIORITY APPLN. INFO.: US 1998-72719P P 19980127
WO 1999-US1663 W 19990127
OTHER SOURCE(S): MARPAT 131:116084
GI



AB Title compds. [I; R = X2Y2R1; R1 = H, alkyl, (hetero)aryl, etc.; R3,R4 = H, alkyl, (hetero)aryl(alkyl), etc.; R5 = X1Y1R2; R2 = H, alkyl, alkoxy, (di)alkylamino, (hetero)aryl(alkyl), etc.; R6 = H, (un)substituted alkyl, (di)(alkyl)amino, etc.; X1 = bond, CH2, CO, SO2, etc.; X2 = CO, CS, So2; Y1 =bond, alkylene, CH:CH, etc.; Y2 = bond, CH2, O, NH, CH:CH, etc.; Z = CH2 or CH2CH2; dashed line = optional addnl. bond] were prepd. Thus, 7-nitro-1-tetralone was converted in 4 steps to trans-1-amino-7-nitro-2-naphthol which was amidated by 4-EtC6H4SO2Cl and the reduced product N-alkylated by 4-(F3CO)C6H4CH2Br to give title compd. trans-II. Data for biol. activity of I were given.

IT **232265-96-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as potassium channel blockers)

RN 232265-96-2 CAPLUS

CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl](3-pyridinylmethyl)amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 25 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:325919 CAPLUS
DOCUMENT NUMBER: 130:352284
TITLE: Preparation of 5-benzylidenethiazolidine-2,4-dione and 10-[4-[(2,4-dioxothiazolidin-5-ylidene)methyl]phenyl]-5H-dibenzo[b,e][1,4]diazepine derivatives as retinoid receptor agonists
INVENTOR(S): Kagechika, Hiroyuki; Hashimoto, Yuichi; Itai, Akiko
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924415	A1	19990520	WO 1998-JP5091	19981112
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2309331	AA	19990520	CA 1998-2309331	19981112
AU 9910525	A1	19990531	AU 1999-10525	19981112
EP 1048659	A1	20001102	EP 1998-953024	19981112
R: CH, DE, FR, GB, IT, LI				

PRIORITY APPLN. INFO.: JP 1997-310835 A 19971112
WO 1998-JP5091 W 19981112
OTHER SOURCE(S): MARPAT 130:352284
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I; R1-R5 = H or lower alkyl or adjacent 2 groups of R1-R5 form together with the carbon atoms of the Ph ring to from 5- to 6-membered ring optionally 1 or .gtoreq.2 alkyl groups; X = CR6:CH, CH:CR7, NR8CO, CONR9, C(:CHR10), CO, or NR11; R6-R11 = H lower alkyl) and (II; R21-R24 = H or lower alkyl or adjacent 2 groups of R1-R5 form together with the carbon atoms of the Ph ring to from 5- to 6-membered ring optionally 1 or .gtoreq.2 alkyl groups; R25 = H, lower alkyl), which are retinoid receptor agonists having retinoic effects or regulatory effects of increasing or suppressing retinoid actions, are prepd. These compds. are useful for the prevention and/or treatment of cancers, diabetes, arteriosclerosis, bone diseases, rheumatism, and autoimmune diseases. Thus, 4-[1-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)vinyl]benzaldehyde was condensed with 2,4-thiazolidinedione in the presence of piperidine and AcOH in toluene under reflux at 120.degree. to give the title compd. (III). III in vitro promoted the differentiation of HL-60 cell to granulocyte by 2.8, 6.4, and 89% at 10-8, 10-7 and 10-6 M, resp., and 76, and 84, and 92% in the copresence of 3.times.10-9 M Am80, resp.

IT **224629-74-7P 224629-75-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzylidenethiazolidinedione and [[(dioxothiazolidinylidene)methyl]phenyl]-5H-dibenzo[b,e][1,4]diazepine derivs. as retinoid receptor agonists as preventives and therapeutics)

RN 224629-74-7 CAPLUS
CN Benzamide, 4-[(2,4-dioxo-5-thiazolidinylidene)methyl]-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 224629-75-8 CAPLUS
CN Benzamide, 3-[(2,4-dioxo-5-thiazolidinylidene)methyl]-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 26 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:589875 CAPLUS
DOCUMENT NUMBER: 129:302528
TITLE: New Platelet Fibrinogen Receptor Glycoprotein IIb-IIIa Antagonists: Orally Active Series of N-Alkylated Amidines with a 6,6-Bicyclic Template
AUTHOR(S): Okumura, Kunio; Shimazaki, Toshiyuki; Aoki, Yoji;

Searched by Barb O'Bryen, STIC 308-4291

Yamashita, Hiroyuki; Tanaka, Eishi; Banba, Shinichi; Yazawa, Kouhei; Kibayashi, Kenji; Banno, Hitoshi
CORPORATE SOURCE: Pharmaceuticals Section Life Sciences Laboratory, Performance Materials RD Center Mitsui Chemicals Inc., Chiba, 297-0017, Japan
SOURCE: Journal of Medicinal Chemistry (1998), 41(21), 4036-4052
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The design, synthesis, and pharmacol. evaluation of (S)-(-)-Et [6-[4-(morpholinoformimidoyl)benzamido]-3,4-dihydro-2H-1-benzopyran-3-yl]acetate hydrochloride ((S)-I.cntdot.HCl, MS-180), an orally active glycoprotein IIb-IIIa (GPIIb-IIIa) antagonist, are reported. Pharmacophore mapping of amidino and carboxyl groups of already known GPIIb-IIIa antagonists led to the synthesis of nine amidino acids contg. 6,6-bicyclic ring skeletons. Among them, the compds. having an amide bond and 1,2,3,4-tetrahydronaphthalene or a 3,4-dihydro-2H-1-benzopyran skeleton showed marked inhibitions with IC50 values of 46-57 nM in human platelet aggregation assay in vitro, but low oral activities. N-Alkylation of the amidino group coupled with the ester prodrug approach afforded (MS-180) (S)-I.cntdot.HCl, which generates in vivo the corresponding (S)-carboxylic acid (II) as an active species. In vitro, II inhibited ADP-induced aggregation of guinea pig, dog, and human platelets (IC50 = 110, 253, and 35 nM, resp.) and inhibited the binding of fibrinogen to immobilized GPIIb-IIIa of human platelets (IC50 = 0.12 nM). After oral administration of MS-180 (S)-I.cntdot.HCl to fasted beagle dog, ex vivo inhibition of platelet aggregation was obsd. The maximal inhibitions were obsd. 2-4 h after dosing with dose dependency (60% inhibition at a dose of 1 mg/kg, 85% at 3 mg/kg, and 100% at 10 mg/kg, resp.) and the extent of the inhibitions paralleled the plasma concn. of the active species II. On the basis of these studies, MS-180 [(S)-I.cntdot.HCl] was selected as a candidate for clin. evaluation as a drug for the treatment and prevention of thrombosis in patients.

IT **188349-90-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of orally active [[(carboxymethyl)aryl]aminocarbonyl]benzamidines as platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists)

RN 188349-90-8 CAPLUS

CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

IT **188349-91-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)
(prepn. of orally active [[(carboxymethyl)aryl]aminocarbonyl]benzamidin es as platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists)

RN 188349-91-9 CAPLUS

CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 27 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:329589 CAPLUS

DOCUMENT NUMBER: 129:76127

TITLE: Novel thiazolidinedione derivatives with retinoid synergistic activity

AUTHOR(S): Ebisawa, Masayuki; Kawachi, Emiko; Fukasawa, Hiroshi; Hashimoto, Yuichi; Itai, Akiko; Shudo, Koichi; Kagechika, Hiroyuki

CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113-0033, Japan

SOURCE: Biological & Pharmaceutical Bulletin (1998), 21(5), 547-549
CODEN: BPBLEO; ISSN: 0918-6158

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB Several arylmethylidene thiazolidinediones were synthesized and their retinoidal activities were examd. TZ181 (I), having a benzanilide skeleton, exhibited differentiation-inducing activity in HL-60 cell assay, while TZ191, the N-methylated analog of TZ181, TZ245 and TZ335 acted as retinoid synergists like the RXR-selective ligand, LGD1069.

IT **209161-82-0P**, TZ 185
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(novel thiazolidinedione derivs. with retinoid synergistic activity)
RN 209161-82-0 CAPLUS
CN Benzamide, 4-[(Z)-(2,4-dioxo-5-thiazolidinylidene)methyl]-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 28 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:244286 CAPLUS
DOCUMENT NUMBER: 126:225229
TITLE: Amidine derivatives and platelet aggregation inhibitor containing the same
INVENTOR(S): Yamashita, Hiroyuki; Okumura, Kunio; Shimazaki, Toshiyuki; Kanematsu, Akihito; Aoki, Yoji; Nakajima, Yuki; Yazawa, Kouhei; Kibayashi, Kenji
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Japan
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 760364	A2	19970305	EP 1996-113937	19960830
EP 760364	A3	19980729		
EP 760364	B1	20000719		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, LI, NL, SE				
US 5719145	A	19980217	US 1996-699346	19960819
AU 9662172	A1	19970508	AU 1996-62172	19960820
AU 686515	B2	19980205		
NO 9603469	A	19970303	NO 1996-3469	19960821
JP 09124581	A2	19970513	JP 1996-226465	19960828
AT 194829	E	20000815	AT 1996-113937	19960830
ES 2149411	T3	20001101	ES 1996-113937	19960830
CN 1154962	A	19970723	CN 1996-113341	19960831
CN 1062266	B	20010221		

PRIORITY APPLN. INFO.: JP 1995-223094 A 19950831
OTHER SOURCE(S): MARPAT 126:225229
GI



I



II



III

AB Substituted amidine derivs. I [A = CONR1, NR1CO; R1 = H, alkyl; B = CH2, O; X = CH, N; X = CH when B = O; Z = H, (un)substituted alkyl; R2, R3, R4 = H, alkyl, CH2C.tplbond.CH, CO2R5, (CH2)mAr; R2R3 = (hetero)cycloalkyl; R5 = alkyl, CH2CH2OMe; m = 1, 2; Ar = pyridyl, furyl, thienyl] have excellent platelet aggregation inhibiting action on the basis of fibrinogen antagonism. Thus, amidine II.cntdot.HCl was prepd. via amination of nitrile III with morpholine, followed by sapon. and acidification. II exhibited inhibition of GPIIb/IIIa fibrinogen binding (IC50 = 0.13 nM), platelet aggregation in guinea pig plasma (IC50 = 140 nM) and in human plasma (IC50 = 68 nM).

IT **188349-90-8P 188349-91-9P 188350-01-8P**
188350-02-9P 188350-03-0P 188350-04-1P
188350-06-3P 188350-07-4P 188350-10-9P
188350-11-0P 188350-27-8P 188350-28-9P
188350-30-3P 188350-33-6P 188350-34-7P
188350-36-9P 188350-38-1P 188350-44-9P
188350-46-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of amidine derivs. as platelet aggregation inhibitors)

RN 188349-90-8 CAPLUS

CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188349-91-9 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-01-8 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-thiomorpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-02-9 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-thiomorpholinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-03-0 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 188350-04-1 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 188350-06-3 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-1-piperidinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-07-4 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-1-piperidinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-10-9 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-1-pyrrolidinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-11-0 CAPLUS
CN 2-Naphthaleneacetic acid, 7-[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]benzoyl]amino]-1,2,3,4-tetrahydro-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-27-8 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(2-pyridinylmethyl)amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 188350-28-9 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(2-pyridinylmethyl)amino]methyl]benzoyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 188350-30-3 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(3-pyridinylmethyl)amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-33-6 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(4-pyridinylmethyl)amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-34-7 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[[2-(4-pyridinyl)ethyl]amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-36-9 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino(4-phenyl-1-piperazinyl)methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 188350-38-1 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, ethyl ester, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 188350-44-9 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● HCl

RN 188350-46-1 CAPLUS
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, monohydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● HCl

L19 ANSWER 29 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:307338 CAPLUS
DOCUMENT NUMBER: 124:343334
TITLE: Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
INVENTOR(S): Chenard, Bertrand L.; Howard, Harry R.; Macor, John E.; Schulz, David W.; Sprouse, Jeffrey S.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 701819	A2	19960320	EP 1995-306249	19950907
EP 701819	A3	19990623		
EP 701819	B1	20000816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5597826	A	19970128	US 1994-306230	19940914
AT 195429	E	20000915	AT 1995-306249	19950907
ES 2148445	T3	20001016	ES 1995-306249	19950907
PT 701819	T	20001229	PT 1995-95306249	19950907
CA 2158108	AA	19960315	CA 1995-2158108	19950912
CA 2158108	C	19990316		
JP 08109130	A2	19960430	JP 1995-236951	19950914

PRIORITY APPLN. INFO.: US 1994-306230 A 19940914
OTHER SOURCE(S): MARPAT 124:343334
GI



AB Claimed is a pharmaceutical compn. contg. a 5-HT re-uptake inhibitor, a pharmaceutically acceptable carrier, and a compd. I [R1 = Q1, etc.; R2 = R4, etc.; R4 = H, CF3, alkyl, alkylaryl, etc.; a proviso is given; R3 = H,

alkyl, aryl, etc.]. Compds. I were assayed for 5-HT1A and 5-HT1D affinity and showed IC50 values of less than 0.6 .mu.M for at least one of said affinities. 7-Benzamido-1-(4-methyl-1-piperazinyl)naphthalene was prepd. in several steps from 7-amino-.alpha.-tetralone.

IT **163465-77-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of piperazinylnaphthalene derivs. as central nervous system agent for use in combination with sertraline)

RN 163465-77-8 CAPLUS

CN Benzamide, N-[5,6-dihydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **163498-81-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of piperazinylnaphthalene derivs. as central nervous system agent for use in combination with sertraline)

RN 163498-81-5 CAPLUS

CN Benzamide, N-[5,6,7,8-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 30 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1996:188897 CAPLUS

DOCUMENT NUMBER: 124:232261

TITLE: Preparation of N-(indanylmethyl)piperidines and -piperazines and analogs as 5-HT1A and/or 5-HT2A ligands

INVENTOR(S): Perregaard, Jens Kristian; Stenberg, John Willie; Hansen, Bitten

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

Searched by Barb O'Bryen, STIC 308-4291

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9533721	A1	19951214	WO 1995-DK230	19950608
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9504689	A	19960129	ZA 1995-4689	19950607
IL 114026	A1	19990620	IL 1995-114026	19950607
CA 2192112	AA	19951214	CA 1995-2192112	19950608
AU 9526698	A1	19960104	AU 1995-26698	19950608
AU 685284	B2	19980115		
EP 765311	A1	19970402	EP 1995-921731	19950608
EP 765311	B1	20001004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1154105	A	19970709	CN 1995-194363	19950608
BR 9507929	A	19970909	BR 1995-7929	19950608
HU 76464	A2	19970929	HU 1996-3371	19950608
JP 10501524	T2	19980210	JP 1995-500194	19950608
RU 2142458	C1	19991210	RU 1997-100181	19950608
SK 280824	B6	20000814	SK 1996-1550	19950608
AT 196760	E	20001015	AT 1995-921731	19950608
ES 2151601	T3	20010101	ES 1995-921731	19950608
CZ 287629	B6	20010117	CZ 1996-3590	19950608
PT 765311	T	20010330	PT 1995-95921731	19950608
PL 183096	B1	20020531	PL 1995-317531	19950608
FI 9604898	A	19961205	FI 1996-4898	19961205
NO 9605195	A	19970130	NO 1996-5195	19961205
US 6218394	B1	20010417	US 1996-999868	19961209
US 2003195356	A1	20031016	US 2000-549861	20000414

PRIORITY APPLN. INFO.:
DK 1994-649 A 19940608
WO 1995-DK230 W 19950608
US 1996-999868 A1 19961209

OTHER SOURCE(S): MARPAT 124:232261
GI



I



II

AB Title compds. [I; R = Ph, naphthyl, heteroaryl; R1 = H, (cyclo)alk(en)yl, aryl, acyl, etc.; R2 = H, alkyl, cycloalkyl(alkyl); R1R2 = atoms to form a ring; R3-R5 = H, halo, alkyl, alkanoyl, COPh, etc.; R6-R8 = H, alkyl; R6R7 = alkylene; 1 of X,Y = CH2 and the other = CH2, O, S; Z = N, CH, COH; when dashed line = addnl. bond Z = C] were prepd. Thus, 6-nitro-1-indancarboxylic acid (prepn. given) was amidated by 4-(4-fluorophenyl)piperidine and the product converted in 2 steps to title compd. II (R1 = H, dashed line = null). II (R1 = Ac, dashed line = bond) had IC50 of 11 and 2.8nM against ligand binding at 5-HT1A and 5-HT2A receptors in vitro, resp.

IT **174776-05-7P 174776-06-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(indanylmethyl)piperidines and -piperazines and analogs as 5-HT1A and/or 5-HT2A ligands)

RN 174776-05-7 CAPLUS
CN Cyclopropanecarboxamide, N-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]-2,3-dihydro-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



RN 174776-06-8 CAPLUS
CN Cyclopentanecarboxamide, N-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]-2,3-dihydro-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 31 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:580492 CAPLUS
DOCUMENT NUMBER: 122:314570
TITLE: Preparation of heterocyclylnaphthalene derivatives as serotonin 5-HT1 agonists and antagonists.
INVENTOR(S): Chenard, Bertrand L.; Macor, John E.; Segelstein, Barbara E.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421619	A1	19940929	WO 1994-US1206	19940215
W: AU, BR, CA, CN, CZ, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9463918	A1	19941011	AU 1994-63918	19940215
EP 689536	A1	19960103	EP 1994-911377	19940215
EP 689536	B1	20010523		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				

JP 08503228	T2	19960409	JP 1994-521019		19940215
ES 2157256	T3	20010816	ES 1994-911377		19940215
HU 67312	A2	19950328	HU 1994-760		19940312
FI 9401213	A	19940917	FI 1994-1213		19940315
CA 2158457	AA	19940929	CA 1994-2158457		19940315
CA 2158457	C	20010417			
ZA 9401806	A	19950915	ZA 1994-1806		19940315
US 2001004669	A1	20010621	US 2001-758074		20010110
US 2002058811	A1	20020516	US 2001-4990		20011203
PRIORITY APPLN. INFO.:			US 1993-32042	A	19930316
			WO 1994-US1206	W	19940215
			US 1995-522349	B1	19950915
			US 2001-758074	A1	20010110

OTHER SOURCE(S): MARPAT 122:314570

GI



AB Title compds. [I; R1 = Q1-Q3, etc.; R2 = R4, OR4, OS(O)2R4, NR4R5, R4(CH2)bNH(C:X)(CH2)c, R4(CH2)bO(C:O)NH(CH2)c(C:O)NH, R4(C:O)NH(C:O)NH, (CH2)bNH(C:X)(CH2)bO(C:O)(CH2)cR4, NH(C:X)NHR4, R4O(C:O)O, O(C:O)NHR4, R4O(C:O)NH, (CH2)b(C:O)(CH2)cR4, NHS(O)2R4, C(OH)R4R5, CH(OH)R4, (C:O)NR4R5, CN, NO2, substituted alkyl, (substituted) alkenyl, alkynyl; R3 = H, alkyl, alkylaryl, aryl; R4, R5 = Q4, Q5, H, CF3, alkyl, alkylaryl, etc.; R6-R14 = H, halo, CF3, CN, NO2, aryl, alkylaryl, alkyl, alkenyl, alkynyl, OR20, COR20, NR20R21, etc.; adjacent pairs of R6-R14 = atoms to form 5-7 membered rings; R20, R21 = H, alkyl, aryl, alkylaryl; R20R21 = atoms to form 4-7 membered rings; A, B, D, E, F, L = C, N; G, I, J, K = C, N, O, S, C:O; X = O, S; a = 0-2; b, c = 0-6; dotted line = optional double bond; with provisos], were prepd. These compds. are useful psychotherapeutics and are potent serotonin (5-HT1) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache assocd. with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compds. can also be used as centrally acting antihypertensives and vasodilators. Thus, 7-amino-.alpha.-tetralone was stirred with PhCOCl/Et3N in THF to give 85% 7-benzamido-.alpha.-tetralone. This in THF at -78.degree. was treated with N-methylpiperazine and TiCl4 to give 83% 7-benzamido-1-(4-methyl-1-piperazinyl)-3,4-dihydronaphthalene. The latter was refluxed with Pd/C in xylene to give title compd. 7-benzamido-1-(4-methyl-1-piperazinyl)naphthalene and 7-benzamido-1-(4-methyl-1-piperazinyl)-1,2,3,4-tetrahydronaphthalene. I showed IC50 <0.60

nM for 5-HT1A and/or 5-HT1D affinity.

IT **163498-81-5P**
RL: BYP (Byproduct); PREP (Preparation)
(prepn. of heterocyclylnaphthalene derivs. as serotonin 5-HT1 agonists and antagonists)
RN 163498-81-5 CAPLUS
CN Benzamide, N-[5,6,7,8-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **163465-77-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclylnaphthalene derivs. as serotonin 5-HT1 agonists and antagonists)
RN 163465-77-8 CAPLUS
CN Benzamide, N-[5,6-dihydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 32 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:495955 CAPLUS
DOCUMENT NUMBER: 121:95955
TITLE: Dyes and compositions for yellow color toners
INVENTOR(S): Takuma, Hirosuke; Shimokawa, Yasushi; Matsuzaki, Yoriaki; Aida, Isamu; Koshida, Hitoshi
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 05333599 A2 19931217 JP 1992-138958 19920529
PRIORITY APPLN. INFO.: JP 1992-138958 19920529
GI



I

AB The title dyes have the general formula I [R1-5 = H, C1-8 alkyl, cycloalkyl alkoxy, alkoxyalkoxy, (substituted) phenoxy, thioalkoxy, alkylsulfonyl, (substituted) thiophenoxy, alkoxycarbonyl, alkylaminocarbonyl, halo, CN; R6-9 = H, C1-8 alkyl, cycloalkyl, alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkoxycarbonylalkoxycarbonyl, alkylaminocarbonyl, (substituted) phenoxy, NO2, NH2, (substituted) alkylamino, (substituted) alkylcarbonylamino, (substituted) allylcarbonylamino, (substituted) arylcarbonylamino, (substituted) alkylcarboxy, (substituted) allylcarboxy, (substituted) arylcarboxy, halo]. The toner compns. contain .gtoreq.1 of the dyes. The dyes show good compatibility when melt-kneaded and the toner using them provide yellow images with good uniformity in d. and good lightfastness in repeated copying. Thus, Himer TB-1000F (styrene-acrylic resin) and I (R1-6 = R8 = R9 = H, R7 = tert-Bu) were melt-kneaded and pulverized to give a toner, which was mixed with an Fe powder to give a developer.

IT **156456-08-5**
RL: USES (Uses)
(yellow dye, for electrophotog. toner)

RN 156456-08-5 CAPLUS
CN Benzamide, N-[2-(6-butyl-3-hydroxy-2-quinolinyl)-2,3-dihydro-1,3-dioxo-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 33 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:124080 CAPLUS
DOCUMENT NUMBER: 116:124080
TITLE: Radioiodinated benzovesamicol analogs for cholinergic nerve mapping
INVENTOR(S): Wieland, Donald M.; Jung, Yong Woom; Van Dort, Marcian E.; Gildersleeve, David L.
PATENT ASSIGNEE(S): University of Michigan, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2

Searched by Barb O'Bryen, STIC 308-4291

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9117776	A1	19911128	WO 1991-US3273	19910510
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5077035	A	19911231	US 1990-523233	19900514
CA 2082797	AA	19911115	CA 1991-2082797	19910510
JP 05509304	T2	19931222	JP 1991-510975	19910510
EP 648130	A1	19950419	EP 1991-911403	19910510
EP 648130	B1	19981230		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 175125	E	19990115	AT 1991-911403	19910510

PRIORITY APPLN. INFO.: US 1990-523233 19900514
WO 1991-US3273 19910510

OTHER SOURCE(S): MARPAT 116:124080
GI



I

AB Radioiodinated benzovesamicol analogs (I; X = H, OH, NH2, NHCO-3-[1]-Ph, radioactive isotope of I; Y = H, radioactive I; .gtoreq.1 of X or Y contains radioactive I) selectively localize in presynaptic cholinergic neurons and are thus useful for brain imaging. (-)-5-Iodobenzovesamicol (II), prepd. from (.+-.)-5-aminobenzovesamicol (prepn. given), was labeled with 125I by exchange with Na[125I] I at 150.degree. in the presence of (NH4)2SO4. II gave marked accumulation of radioactivity in the striatum and cerebral cortex following i.v. injection in mice.

IT **139399-87-4D**, radioiodine-labeled **139399-88-5D**, radioiodine-labeled **139399-89-6D**, radioiodine-labeled
RL: BIOL (Biological study)
(brain imaging with cholinergic neuron-selective)

RN 139399-87-4 CAPLUS

CN Benzamide, 2-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139399-88-5 CAPLUS
CN Benzamide, 3-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139399-89-6 CAPLUS
CN Benzamide, 4-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **139399-88-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for brain imaging agent prepn.)
RN 139399-88-5 CAPLUS
CN Benzamide, 3-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L19 ANSWER 34 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:666700 CAPLUS
DOCUMENT NUMBER: 115:266700
TITLE: Silver halide photographic materials
INVENTOR(S): Sugita, Shuichi; Kida, Shuji; Oya, Hidenobu

Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03107138	A2	19910507	JP 1989-244632	19890920
JP 2729678	B2	19980318		

PRIORITY APPLN. INFO.: JP 1989-244632 19890920
GI For diagram(s), see printed CA Issue.
AB The title materials contain compds. that react with oxidized developer and liberate group I (X = O, CRR1; R, R1 = H, alkyl, cycloalkyl, alkenyl, aryl; Y = N, CR2; R2 = H, alkyl, cycloalkyl, alkenyl, aryl; PUG = photog. useful group; Z = nonarom. 5-7-membered ring). These materials can be made to have high storage stability, image sharpness, fine grain, or color reproducibility (and/or interimage effect). Thus, a green-sensitive Ag(I,Br) emulsion was added with 0.4 mmol/mol Ag II and magenta coupler was applied on triacetate film base. Obtained film was exposed and normally processed, and showed better graininess and sharpness than parallel run with film contg. known ref. compds.
IT **137428-02-5**
RL: USES (Uses)
(agent releasing photog. useful compd., color photog. film contg.)
RN 137428-02-5 CAPLUS
CN 1H-Indole-2-acetic acid, 1-[(4,5-dihydro-5-oxo-4-phenyl-1H-tetrazol-1-yl)carbonyl]-2,3-dihydro-, 2,3-dihydro-4-[[2-(octadecyloxy)benzoyl]amino]-1-oxo-1H-inden-2-yl ester (9CI) (CA INDEX NAME)



L19 ANSWER 35 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:428910 CAPLUS
DOCUMENT NUMBER: 115:28910
TITLE: Preparation of benzanilides and analogs as anticancer and dermatological agents
INVENTOR(S): Klaus, Michael; Mohr, Peter
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE: Eur. Pat. Appl., 14 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 410358	A1	19910130	EP 1990-114101	19900723
EP 410358	B1	19930929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2020887	AA	19910129	CA 1990-2020887	19900711
US 5128470	A	19920707	US 1990-551831	19900712
ZA 9005738	A	19910327	ZA 1990-5738	19900720
IL 95144	A1	19941007	IL 1990-95144	19900720
HU 54106	A2	19910128	HU 1990-4577	19900723
HU 204773	B	19920228		
AT 95167	E	19931015	AT 1990-114101	19900723
ES 2059919	T3	19941116	ES 1990-114101	19900723
JP 03074353	A2	19910328	JP 1990-195092	19900725
JP 07005533	B4	19950125		
AU 9059892	A1	19910131	AU 1990-59892	19900726
AU 637623	B2	19930603		
NO 9003351	A	19910129	NO 1990-3351	19900727
CZ 277709	B6	19930317	CZ 1990-3740	19900727
SU 1811525	A3	19930423	SU 1990-4830538	19900727
US 5216153	A	19930601	US 1992-852607	19920317
PRIORITY APPLN. INFO.:			CH 1989-2818	19890728
			US 1990-551831	19900712
			EP 1990-114101	19900723

OTHER SOURCE(S): MARPAT 115:28910

GI



I



II

AB The title compds. [I; M = CONH, NHCO; R1 = H, halo, OR5; R2 = H, alkyl, alkoxy, halo; R3, R4 = alkyl; R3R4 = alkylene; R5 = H, acyl, alkoxycarbonyl, (un)substituted alkyl] were prepd. Thus, 4-(H2N)C6H4OH was condensed with 4-(2-chloroethyl)morpholine and the product condensed with 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenecarboxylic acid to give title compd. II, which reduced from 78% (controls) to 16% the percentage increase in no. of mammary tumors induced by 7,12-dimethylbenz[a]anthracene in rats at 200 mg/kg/day orally.

IT **134599-37-4P 134599-40-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anticancer and dermatol. agent)

RN 134599-37-4 CAPLUS

CN Benzamide, 4-[2-(4-morpholinyl)ethoxy]-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 134599-40-9 CAPLUS
CN Benzamide, N-(2,3-dihydro-1,1,3,3-tetramethyl-1H-inden-5-yl)-4-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



L19 ANSWER 36 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:523758 CAPLUS
DOCUMENT NUMBER: 115:123758
TITLE: Heat-developable color photographic materials
INVENTOR(S): Kato, Katsunori; Mizukoshi, Gunji; Kato, Midori; Komamura, Tawara
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02289854	A2	19901129	JP 1990-39330	19900220

PRIORITY APPLN. INFO.: JP 1989-39549 19890220
OTHER SOURCE(S): MARPAT 115:123758
AB The title material comprises a photosensitive Ag halide, a reducing agent, a binder, and a dye-releasing compd. BLADn [A = coupler capable of forming a dye by reacting with an oxidized reducing agent; L = divalent group bonded to the coupling position of A; B = ballast group; D = moiety of a dye having a max. absorption wavelength .gtoreq.725 nm; and n = 1, 2, 3; A and D may have a portion in common].
IT **135729-02-1**
RL: USES (Uses)
(photothermog. dye releasing coupler)
RN 135729-02-1 CAPLUS
CN Benzamide, N-[1,3-bis(dicyanomethylene)-2-[[4-[ethyl(2-methoxyethyl)amino]-2-methylphenyl]imino]-2,3-dihydro-1H-inden-5-yl]-4-[4-[1,3-dihydro-1,3-dioxo-5-[(1-oxononadecyl)amino]-2H-isoindol-2-yl]-4,5-dihydro-3-[(2-methyl-1-oxopropyl)amino]-5-oxo-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L19 ANSWER 37 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:27977 CAPLUS
DOCUMENT NUMBER: 112:27977
TITLE: Direct-positive silver halide color photographic material containing development inhibitor-releasing compound
INVENTOR(S): Yoshizawa, Tomomi; Ogi, Keiji
PATENT ASSIGNEE(S): Konica Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01013146	A2	19890118	JP 1987-169425	19870706

PRIORITY APPLN. INFO.: JP 1987-169425 19870706

AB In the title material having on a support .gtoreq.1 each of a blue-sensitive emulsion layer, a green-sensitive emulsion layer, and a red-sensitive emulsion layer each contg. a color coupler, an essentially noncolor image-forming layer contg. a photosensitive Ag halide emulsion and a development inhibitor-releasing compd. is formed adjoining to .gtoreq.1 of the above emulsion layers.

IT **82151-61-9**
RL: USES (Uses)
(direct-pos. color photog. materials contg.)
RN 82151-61-9 CAPLUS
CN Benzamide, N-[2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-2,3-dihydro-1-oxo-1H-inden-4-yl]-2-(octadecyloxy)- (9CI) (CA INDEX NAME)



L19 ANSWER 38 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:587232 CAPLUS
DOCUMENT NUMBER: 107:187232
TITLE: Silver halide color photographic development
INVENTOR(S): Ishikawa, Masao; Koboshi, Shigeharu; Kuze, Satoru; Kobayashi, Kazuhiro; Kurematsu, Masayuki
PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62079448	A2	19870411	JP 1985-221082	19851003

PRIORITY APPLN. INFO.: JP 1985-221082 19851003

AB The development has the following characteristics for improving its stability nearly independent of the variation in the concn. of Br- or thiosulfate salts and providing color images with improved storage stability. The photog. material suitable for the development contains practically Ag(Cl,Br) in .gtoreq.1 Ag halide emulsion layer, a binder having a film-swelling rate T1/2 <30 s, and a development inhibitor-releasing agent of the formula A1-Z1 or A2-TIME-Z2 (A1, A2 = coupler component; Z1, Z2 = development inhibitor component; TIME = timing group). It is effected at >30.degree. for <150 s by using a color developing soln. contg. an N-hydroxyalkyl-substituted p-phenylenediamine deriv.

IT **82151-61-9**
RL: USES (Uses)
(color photog. development inhibitor-releasing compd., for improved stability in development and color images with improved storage stability)
RN 82151-61-9 CAPLUS
CN Benzamide, N-[2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-2,3-dihydro-1-oxo-1H-inden-4-yl]-2-(octadecyloxy)- (9CI) (CA INDEX NAME)



L19 ANSWER 39 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:603692 CAPLUS
DOCUMENT NUMBER: 103:203692
TITLE: Silver halide color photographic photosensitive materials
PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 33 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60128445	A2	19850709	JP 1983-237650	19831215
JP 05001454	B4	19930108		

PRIORITY APPLN. INFO.: JP 1983-237650 19831215
GI



I

AB Ag halide color photog. photosensitive materials having .gtoreq.1 red-sensitive emulsion layer, .gtoreq.1 green-sensitive emulsion layer and .gtoreq.1 blue-sensitive emulsion layer are claimed in which .gtoreq.1 of the red- and blue-sensitive emulsion layers contains an org. development inhibitor-releasing compd. and the green-sensitive emulsion layers contains 5 .times. 10-5 to 2 .times. 10-o mol/mol Ag halide of an org. development inhibitor whose Ag salt has a pKsp value (= -log L, where L is soly. product) of 12.0-15.5. Thus, a color photog. neg. film having (1) a halation inhibitor layer, (2) an interlayer, (3) a low-sensitivity red-sensitive layer, (4) a high-sensitivity red-sensitive emulsion layer, (5) an interlayer, (6) a low-sensitivity green-sensitive emulsion layer,

(7) a high-sensitivity green-sensitive emulsion layer, (8) an interlayer, (9) a yellow filter layer, (10) a low-sensitivity blue-sensitive layer, (11) a high-sensitivity blue-sensitive layer, (12) an interlayer, and (13) a protective layer was prepd. by adding the development inhibitor 1-ethyl-2-mercapto-5-amino-1,3,4-triazole (pKsp = 13.8) in the layer 6 and development inhibitor-releasing compd. I in the layer 10. The photog. film showed excellent color tone reproducibility.

IT **82151-61-9**
RL: USES (Uses)
(development inhibitor-releasing compd., color photog. photosensitive materials contg.)

RN 82151-61-9 CAPLUS
CN Benzamide, N-[2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-2,3-dihydro-1-oxo-1H-inden-4-yl]-2-(octadecyloxy)- (9CI) (CA INDEX NAME)



L19 ANSWER 40 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1983:622308 CAPLUS
DOCUMENT NUMBER: 99:222308
TITLE: Blocked magenta dye-forming couplers
PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58113939	A2	19830707	JP 1981-213899	19811226

PRIORITY APPLN. INFO.: JP 1981-213899 19811226

GI For diagram(s), see printed CA Issue.

AB Magenta couplers of the general formula I or II (A = group of nonmetallic atoms required to form with N a magenta dye-forming coupler; RZ(C(:Z1))m, RZSOn = blocking moiety; Z, Z1 = O, S; m, n = 1, 2; R = mol. bound with Z at an active site, and capable of coupling with the oxidized form of a developer) are used in Ag halide color photog. and show a high rate and high max. d. of coloring and improved preservability. Thus, a triacetate film support was coated with a color photosensitive layer contg. III, tricresyl phosphate, Alkanol B, and a Ag(Br,I) emulsion, wedge-exposed and processed to give a magenta dye image with high sensitivity and max. d. After treatment at 50.degree. and 80 % relative humidity for 3 d, the material showed little degrdn. with respect to sensitivity and max. d.

IT **87194-88-5**
RL: USES (Uses)

(photog. blocked yellow coupler)
RN 87194-88-5 CAPLUS
CN 1H-Pyrazolo[5,1-c]-1,2,4-triazole-1-carbothioic acid, 3-[3-[(butylsulfonyl)amino]phenyl]-6-methyl-, S-[4-[[2-(dodecyloxy)benzoyl]amino]-2,3-dihydro-1-oxo-1H-inden-2-yl] ester (9CI) (CA INDEX NAME)



L19 ANSWER 41 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:414744 CAPLUS
DOCUMENT NUMBER: 97:14744
TITLE: Silver halide photographic material
PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56083742	A2	19810708	JP 1979-160876	19791213
JP 61057622	B4	19861208		

PRIORITY APPLN. INFO.: JP 1979-160876 19791213
GI



I

AB In a Ag halide color photog. film in which a DIR coupler is incorporated in the Ag halide emulsion layer or an adjacent hydrophilic colloidal layer, a hydroquinone deriv. [I; m, n = 1-3; m + n = 2-4; R = hydrocarbon moieties; sum of C atoms in R .ltoreq.8; R1 = halo] is added to the

DIR-contg. layer on the adjacent colloidal layer. The hydroquinone does not react with the DIR, does not lower the sensitivity of the film, and prevents fogging.

IT **82151-61-9**
RL: USES (Uses)
(color photog. emulsions contg. hydroquinone deriv. and DIR coupler of, with reduced fogging)

RN 82151-61-9 CAPLUS

CN Benzamide, N-[2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-2,3-dihydro-1-oxo-1H-inden-4-yl]-2-(octadecyloxy)- (9CI) (CA INDEX NAME)



L19 ANSWER 42 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1978:414797 CAPLUS
DOCUMENT NUMBER: 89:14797
TITLE: Photographic color diffusion transfer material
INVENTOR(S): Deguchi, Hidetaka; Takahashi, Jiro; Kunieda, Naoshi
PATENT ASSIGNEE(S): Konishiroku Photo Industry Co., Ltd., Japan
SOURCE: Ger. Offen., 54 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2729820	A1	19780105	DE 1977-2729820	19770701
DE 2729820	B2	19790823		
DE 2729820	C3	19800522		
JP 53003819	A2	19780113	JP 1976-78057	19760701
JP 60004977	B4	19850207		
US 4149892	A	19790417	US 1977-810910	19770629

PRIORITY APPLN. INFO.: JP 1976-78057 19760701

GI For diagram(s), see printed CA Issue.

AB Diffusion-transfer color photog. materials of improved stability, which give color images having decreased discoloration and color stains and a clear and stable color tone and which have a decreased processing time, contain the developer-releasing-redox compd. I (R = H, halo; R1 = a chromophore group; Z = the atoms to form a 5-7-membered nonarom. hydrocarbon ring; Z1 = divalent group; X = 0, NR3 where R3 is OH or an amino group). Thus, a transparent poly(ethylene terephthalate) support was coated with a green-sensitive gelatin-Ag(Br,I) emulsion layer at 1.1 .mu.m dry thickness, a layer contg. gelatin and II at 1.5 .mu.m dry thickness, and a gelatin protective layer at 0.9 .mu.m dry thickness. This material was then imagewise exposed, combined with a receptor

material, and processed to give a Dmax of 1.92 and a Dmin of 0.21.

IT **66518-40-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 66518-40-9 CAPLUS
CN Benzamide, N-[2-[[[4-[[[4-[(3-bromo-4-hydroxyphenyl)amino]-4,5-dihydro-1-methyl-5-oxo-1H-pyrazol-3-yl]amino]carbonyl]phenyl]sulfonyl]amino]-2,3-dihydro-1-oxo-1H-inden-4-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L19 ANSWER 43 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1974:433149 CAPLUS
DOCUMENT NUMBER: 81:33149
TITLE: Chemotherapeutic nitroheterocycles. XIII. Substituted 2-(5-nitro-2-imidazolylmethylene)-5-amino-1-indanones, -4'-amino-acetophenones, and -6-amino-1-tetralones
AUTHOR(S): Rufer, C.; Kessler, H. J.; Schroeder, E.; Damerius, A.
CORPORATE SOURCE: Res. Lab., Schering A.-G., Berlin/Bergkamen, Fed. Rep. Ger.
SOURCE: Chimica Therapeutica (1973), 8(5), 567-70
CODEN: CHTPBA; ISSN: 0009-4374
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Ketones such as 2-(5-nitro-2-imidazolylmethylene)-5-amino-1-indanones, 4'-aminoacetophenones, and 6-amino-1-tetralones which were alkylated in the 1 position of the imidazole ring and whose amino groups were partly

mono- or dimethylated or acylated were synthesized. In addn. to an extraordinary trichomonacide activity in vitro, 5-amino-2-(5-nitro-1-methyl-2-imidazolylmethylene)-1-indanone (I) [31435-80-0] had good antibacterial activity against Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. While modification of I led to a loss of the antibacterial activity, different derivs. were active in vivo against Trichomonas vaginalis, the ED50 value of a tetralone deriv. ranging in the order of the value of metronidazole.

IT **51981-62-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and bactericidal activity of)

RN 51981-62-5 CAPLUS

CN Benzamide, N-[5,6,7,8-tetrahydro-6-[(1-methyl-5-nitro-1H-imidazol-2-yl)methylene]-5-oxo-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 44 OF 64 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1970:509549 CAPLUS

DOCUMENT NUMBER: 73:109549

TITLE: Synthetic schistosomicides. XVIII. N-(4-[[2-(Diethylamino)ethyl]amino]-1-naphthyl)amides, N-[5,6,7,8-tetrahydro-4-[(3-piperidinopropyl)amino]-1-naphthyl]amides, and related amide and urea derivatives

AUTHOR(S): Werbel, Leslie M.; Battaglia, Josephine; Elslager, Edward F.; Youngstrom, Carl

CORPORATE SOURCE: Div. of Med. and Sci. Affairs, Parke, Davis and Co., Ann Arbor, MI, USA

SOURCE: Journal of Medicinal Chemistry (1970), 13(4), 592-8
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 73:109549

GI For diagram(s), see printed CA Issue.

AB I (R = alkyl, aryl, aralkyl, 2-furyl, 2-thienyl), II (n = 0 or 4), and III were prepd. by treating N-(4-amino-5,6,7,8-tetrahydro-1-naphthyl)-2,2,2-trifluoro-N-[3- (piperidino)propyl]acetamide with the appropriate acid chloride or anhydride in pyridine, benzene, or HOAc. N-[4-[[2-(Diethylamino)ethyl]-amino]-1-naphthyl]ureas, thioureas, and sulfonamides were also prepd. I and III (R = Ph) had schistosomicidal activity and cured Schistosoma mansoni infections in mice at diet or gavage doses ranging from 45 to 326 mg/kg per day for 3 to 14 days. Four amides also had activity against S. mansoni in Rhesus monkeys. Structure-activity relations were discussed.

IT **26419-24-9P 28785-26-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 26419-24-9 CAPLUS

CN Benzamide, N-[5,6,7,8-tetrahydro-4-[[3-(1-piperidinyl)propyl]amino]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 28785-26-4 CAPLUS
CN Benzoic acid, compd. with N-[5,6,7,8-tetrahydro-4-[(3-piperidinopropyl)amino]-1-naphthyl]benzamide (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 26419-24-9
CMF C25 H33 N3 O



CM 2

CRN 65-85-0
CMF C7 H6 O2



L19 ANSWER 45 OF 64 USPATFULL on STN

ACCESSION NUMBER:	2003:330575 USPATFULL			
TITLE:	Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase			
INVENTOR(S):	Leonard, Daniele Marie, Ann Arbor, MI, UNITED STATES Repine, Joseph Thomas, Ann Arbor, MI, UNITED STATES Rewcastle, Gordon William, Auckland, NEW ZEALAND			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003232790	A1	20031218	
APPLICATION INFO.:	US 2002-257128	A1	20021008	(10)
	WO 2001-US12433		20010417	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Steven R Eck, Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105			
NUMBER OF CLAIMS:	23			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1790			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides dihydro-2H-napthalene-1-ones of formula (V), and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, which are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis. Specifically, the present invention relates to compounds that inhibit the farnesyl transferase enzyme. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **367267-19-4P 367267-35-4P**, N-[2-[2-(5-Benzylimidazol-1-yl)ethoxy]-5-oxo-5,6,7,8-tetrahydronaphthalene-1-yl]benzamide (prepn. and formulation of imidazolyl-substituted dihydronaphthalenones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases)

RN 367267-19-4 USPATFULL

CN Benzamide, N-[5,6,7,8-tetrahydro-5-oxo-2-[2-[1-(phenylmethyl)-1H-imidazol-5-yl]ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 367267-35-4 USPATFULL

CN Benzamide, N-[5,6,7,8-tetrahydro-5-oxo-2-[2-[5-(phenylmethyl)-1H-imidazol-

1-yl]ethoxy]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 46 OF 64 USPATFULL on STN

ACCESSION NUMBER:	2003:277329 USPATFULL
TITLE:	4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
INVENTOR(S):	Perregaard, Jens Kristian, Jaegerspris, DENMARK Stenberg, John Willie, Copenhagen, DENMARK Hansen, Bitten, Koge, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003195356	A1	20031016
APPLICATION INFO.:	US 2000-549861	A1	20000414 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-999868, filed on 9 Dec 1996, GRANTED, Pat. No. US 6218394 Continuation of Ser. No. WO 1995-DK230, filed on 8 Jun 1995, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1994-649	19940608

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Darby & Darby P C, 805 Third Avenue, New York, NY, 10022
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
LINE COUNT:	1544

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 4-Aryl-1-(indanmethyl, dibydrobenzofuramethyl or dihydrobenzotbiophenemethyl) piperidine, -tetrabydropyridine or -piperazine compounds of general formula (I) ##STR1##

wherein one of X and Y is CH.sub.2, and the other one is CH.sub.2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R.sup.1 is hydrogen, alkyl, cycloalkyl, cycloakylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifloromethylsulfonyl, arylsulfonyl, a group R.sup.9VCO-- where V is O or S and R.sup.9 is alkyl or aryl, or a group R.sup.10R.sup.11NCO or R.sup.10R.sup.11NCS-- wherein R.sup.10 and R.sup.11 are hydrogen, alkyl or aryl, or R.sup.10 and R.sup.11 are linked to form a ring R.sup.2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl; or R.sup.1 and R.sup.2 are linked to form a ring; R.sup.3--R.sup.5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylaLkyl or nitro; R.sup.6 and R.sup.7 are bydrogen or alkyl or they are linked to constitute a 3-7-membered ring; R.sup.8 is hydrogen or alkyl; have effects at central serotonergic receptors and are therefore useful in the treatment of

certain psychic and neurologic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **174776-05-7P 174776-06-8P**
(prepn. of N-(indanylmethyl)piperidines and -piperazines and analogs as 5-HT1A and/or 5-HT2A ligands)
RN 174776-05-7 USPATFULL
CN Cyclopropanecarboxamide, N-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]-2,3-dihydro-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



RN 174776-06-8 USPATFULL
CN Cyclopentanecarboxamide, N-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]-2,3-dihydro-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 47 OF 64 USPATFULL on STN

ACCESSION NUMBER:	2003:232579 USPATFULL
TITLE:	4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
INVENTOR(S):	Brotherton-Pleiss, Christine E., Sunnyvale, CA, UNITED STATES Madera, Ann Marie, Dublin, CA, UNITED STATES Weikert, Robert James, Boulder Creek, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003162780	A1	20030828	
	US 6627644	B2	20030930	
APPLICATION INFO.:	US 2002-308081	A1	20021202	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336795P	20011203 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ROCHE PALO ALTO LLC, 3431 HILLVIEW AVENUE, PATENT DEPT., M/S A2-250, PALO ALTO, CA, 94304
NUMBER OF CLAIMS:	41
EXEMPLARY CLAIM:	1
LINE COUNT:	2506

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds which are generally muscarinic receptor antagonists and which are represented by Formula I: ##STR1##

wherein p, R.sup.1, R.sup.2, R.sup.3 and A are as defined in the specification, or individual isomers, racemic or non-racemic mixtures of isomers, or acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use and preparation as therapeutic drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **540493-38-7P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-44-5P**, N-[7-[N-Ethyl-N-[[1-[morpholine-4-carbonyl]piperidin-4-yl]methyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]-4-[methanesulfonyl]benzamide **540493-45-6P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid diethylamide **540493-46-7P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid methylamide **540493-47-8P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid phenylamide **540493-48-9P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid amide **540493-49-0P**, 4-[[Ethyl[7-[4-fluorobenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-55-8P**, 4-[[Ethyl[7-[4-trifluoromethylbenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-56-9P**, 4-[[Ethyl[7-[[naphthalene-2-carbonyl]amino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-58-1P**, 4-[[Ethyl[7-[4-methoxybenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-59-2P**, 4-[[[7-[[Biphenyl-4-carbonyl]amino]-1,2,3,4-tetrahydronaphthalen-2-yl]ethylamino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-63-8P**, 4-[[[7-[4-Dimethylaminobenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]ethylamino]methyl]piperidine-1-carboxylic acid isopropylamide **540493-64-9P**, 4-[[[7-[2,4-Difluorobenzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]ethylamino]methyl]piperidine-1-carboxylic acid isopropylamide
(prepn. of 4-piperidinyl alkylamine derivs. as muscarinic receptor antagonists)

RN 540493-38-7 USPATFULL

CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-44-5 USPATFULL

CN Benzamide, N-[7-[ethyl[[1-(4-morpholinylcarbonyl)-4-piperidinyl]methyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 540493-45-6 USPATFULL
CN 1-Piperidinecarboxamide, N,N-diethyl-4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 540493-46-7 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 540493-47-8 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 540493-48-9 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 540493-49-0 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[7-[(4-fluorobenzoyl)amino]-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-55-8 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(trifluoromethyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-56-9 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[(2-naphthalenylcarbonyl)amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-58-1 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[ethyl[1,2,3,4-tetrahydro-7-[(4-methoxybenzoyl)amino]-2-naphthalenyl]amino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-59-2 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[[7-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1,2,3,4-tetrahydro-2-naphthalenyl]ethylamino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-63-8 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[[7-[[4-(dimethylamino)benzoyl]amino]-1,2,3,4-tetrahydro-2-naphthalenyl]ethylamino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 540493-64-9 USPATFULL
CN 1-Piperidinecarboxamide, 4-[[[7-[(2,4-difluorobenzoyl)amino]-1,2,3,4-tetrahydro-2-naphthalenyl]ethylamino]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



IT **540493-42-3P**, 4-[[Ethyl[7-[4-[methanesulfonyl]benzoylamino]-1,2,3,4-tetrahydronaphthalen-2-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester **540493-43-4P**, N-[7-[N-(Ethyl)-N-

((piperidin-4-yl)methyl)amino]-5,6,7,8-tetrahydronaphthalen-2-yl]-4-[methanesulfonyl]benzamide
(prepn. of 4-piperidinyl alkylamine derivs. as muscarinic receptor antagonists)

RN 540493-42-3 USPATFULL

CN 1-Piperidinecarboxylic acid, 4-[[ethyl[1,2,3,4-tetrahydro-7-[[4-(methylsulfonyl)benzoyl]amino]-2-naphthalenyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 540493-43-4 USPATFULL

CN Benzamide, N-[7-[ethyl(4-piperidinylmethyl)amino]-5,6,7,8-tetrahydro-2-naphthalenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 48 OF 64 USPATFULL on STN

ACCESSION NUMBER: 2003:160085 USPATFULL

TITLE: Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion

INVENTOR(S): Ksander, Gary Michael, Milford, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003109700	A1	20030612	
APPLICATION INFO.:	US 2002-181006	A1	20020711	(10)
	WO 2001-EP439		20010116	

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027

NUMBER OF CLAIMS: 14

EXEMPLARY CLAIM: 1

LINE COUNT: 1460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB ##STR1## Compounds of formula (1) wherein R.sub.2--C, R.sub.3--C, R.sub.4--C or R.sub.5--C may be replaced by N; and wherein n is 1, 2 or 3; R.sub.1 is aryl, heteroaryl or (aryl or heteroaryl)-lower alkoxy; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently hydrogen, lower alkyl, lower alkoxy, halo, trifluoromethyl or cyano; R.sub.6 is (i) or (ii) m is 1, 2 or 3; R.sub.7 is hydrogen, lower alkyl (aryl or heteroaryl)-lower alkyl, lower alkoxy, (aryl or heteroaryl)-lower

alkoxy, hydroxy, oxo, lower alkylenedioxy or lower alkanoyloxy; W is O, S or NR.sub.8; R.sub.8 is --COR.sub.a, (iii), --COOR.sub.d, --SO.sub.2R.sub.e, hydrogen, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R.sub.a, R.sub.d and R.sub.e, are independently optionally substituted lower alkyl, cycloalkyl, adamantyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R.sub.b and R.sub.c are independently hydrogen, cycloalkyl, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl) lower alkyl; or R.sub.b and R.sub.c together represent lower alkylene; and pharmaceutically acceptable salts thereof; and enantiomers thereof; which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (apoB) secretion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **351414-67-0P 351414-83-0P**
(prepn. of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion)

RN 351414-67-0 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-83-0 USPATFULL

CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **351414-68-1P 351414-69-2P 351414-70-5P**
351414-71-6P 351414-72-7P 351414-73-8P
351414-74-9P 351414-75-0P 351414-76-1P
351414-77-2P 351414-78-3P 351414-79-4P
351414-80-7P 351414-81-8P 351414-82-9P
351414-84-1P 351414-85-2P 351414-86-3P

351414-87-4P 351414-88-5P 351414-89-6P
351414-90-9P 351414-91-0P 351414-92-1P
351414-93-2P 351414-94-3P 351414-95-4P
351414-96-5P 351414-97-6P 351414-98-7P
351414-99-8P 351415-00-4P 351415-01-5P
351415-02-6P 351415-03-7P 351415-04-8P
(prepn. of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion)

RN 351414-68-1 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-phenyl-1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-69-2 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-methyl-1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-70-5 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(phenylmethyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-71-6 USPATFULL

CN 1-Piperazinecarboxylic acid, 4-[5-[[[4',6-bis(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-72-7 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-73-8 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-morpholinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-74-9 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-morpholinyl)-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-75-0 USPATFULL
CN 4-Piperidinecarboxylic acid, 1-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-76-1 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-methoxy-1-piperidinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-77-2 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2,3-dihydro-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-78-3 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(4-methyl-1-piperidinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-79-4 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[5-[[(4'-fluoro-6-methoxy[1,1'-biphenyl]-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351414-80-7 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[(2R)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-81-8 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[(2S)-2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 351414-82-9 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-84-1 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-(1-piperazinyl)-1H-inden-5-yl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-85-2 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2R)-2,3-dihydro-2-(1-piperazinyl)-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351414-86-3 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(1-oxobutyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-87-4 USPATFULL

CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(4-acetyl-1-piperazinyl)-2,3-dihydro-1H-inden-5-yl]-4',6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-88-5 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-[(4-methylphenyl)sulfonyl]-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-89-6 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(methylsulfonyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-90-9 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(4-pyridinylcarbonyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-91-0 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(methoxyacetyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-92-1 USPATFULL
CN 1-Piperazinecarboxamide, 4-[2,3-dihydro-5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 351414-93-2 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2-(4-benzoyl-1-piperazinyl)-2,3-dihydro-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-94-3 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-[(phenylmethoxy)acetyl]-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-95-4 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(hydroxyacetyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-96-5 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(2-pyridinylmethyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-97-6 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(2-pyridinyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-98-7 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(4-pyridinyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351414-99-8 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[3-methyl-2-[[4-(trifluoromethyl)phenyl]methoxy]benzoyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-00-4 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[5-[[(4'-fluoro-6-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-01-5 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-02-6 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[5-[([1,1'-biphenyl]-2-ylcarbonyl)amino]-2,3-dihydro-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 351415-03-7 USPATFULL
CN [1,1'-Biphenyl]-2-carboxamide, N-[2,3-dihydro-2-[4-(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)-1-piperazinyl]-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 351415-04-8 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[2,3-dihydro-5-[[(4'-methyl[1,1'-biphenyl]-2-yl)carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



IT **351415-07-1**
(prepn. of carboxamides as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein B secretion)
RN 351415-07-1 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[5-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-inden-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



L19 ANSWER 49 OF 64 USPATFULL on STN

ACCESSION NUMBER:	2003:197151 USPATFULL		
TITLE:	Phenyl urea and phenyl thiourea derivatives		
INVENTOR(S):	Coulton, Steven, Horsham, UNITED KINGDOM Johns, Amanda, St Albans, UNITED KINGDOM Porter, Roderick Alan, Ashwell, UNITED KINGDOM		
PATENT ASSIGNEE(S):	SmithKline Beecham p.l.c., Brentford, UNITED KINGDOM (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6596730	B1	20030722
	WO 2000047580		20000817
APPLICATION INFO.:	US 2001-913228		20011205 (9)
	WO 2000-EP1142		20000210
	NUMBER		DATE
PRIORITY INFORMATION:	GB 1999-3241		19990212
	GB 1999-26441		19991108
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Huang, Evelyn Mei		
LEGAL REPRESENTATIVE:	Sieburth, Kathryn L., McCarthy, Mary, Kinzig, Charles M.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1085		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I): ##STR1##

in which:

one of X and Y is N and the other is CH;

Z represents oxygen or sulfur;

and R.sup.1 to R.sup.7 represent various substituent groups;

and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **288326-41-0P**

(prepn. of Ph ureas and thioureas as human orexin receptor antagonists)

RN 288326-41-0 USPATFULL
CN Benzamide, 2-methoxy-5-[[[(2-methyl-1,5-naphthyridin-4-yl)amino]carbonyl]amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)-(9CI) (CA INDEX NAME)



IT **288326-42-1P**
(prepn. of Ph ureas and thioureas as human orexin receptor antagonists)
RN 288326-42-1 USPATFULL
CN Benzamide, 2-methoxy-5-[[[(2-methyl-1,5-naphthyridin-4-yl)amino]carbonyl]amino]-N-(5,6,7,8-tetrahydro-5-hydroxy-2-naphthalenyl)-(9CI) (CA INDEX NAME)



L19 ANSWER 50 OF 64 USPATFULL on STN
ACCESSION NUMBER: 2003:74418 USPATFULL
TITLE: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
INVENTOR(S): Kania, Robert Steven, San Diego, CA, United States
Bender, Steven Lee, Oceanside, CA, United States
Borchardt, Allen J., San Diego, CA, United States
Cripps, Stephan James, San Diego, CA, United States
Hua, Ye, La Jolla, CA, United States
Johnson, Michael David, San Diego, CA, United States
Johnson, Jr., Theodore Otto, San Diego, CA, United States
Luu, Hiep The, San Diego, CA, United States
Palmer, Cynthia Louise, San Diego, CA, United States
Reich, Siegfried Heinz, Solana Beach, CA, United States
Tempczyk-Russell, Anna Marie, Ramona, CA, United States
Teng, Min, San Diego, CA, United States
Thomas, Christine, West Borough, MA, United States
Varney, Michael David, Solana Beach, CA, United States
Wallace, Michael Brennan, San Diego, CA, United States

PATENT ASSIGNEE(S):	Collins, Michael Raymond, San Diego, CA, United States Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6534524	B1	20030318
APPLICATION INFO.:	US 2001-983783		20011025 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-609335, filed on 30 Jun 2000, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-142130P	19990702 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Davis, Zinna Worthington
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	8902

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **319468-45-6P 319468-46-7P**
(prepn. of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

RN 319468-45-6 USPATFULL

CN Benzamide, 2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319468-46-7 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L19 ANSWER 51 OF 64 USPATFULL on STN

ACCESSION NUMBER:	2003:67777 USPATFULL
TITLE:	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
INVENTOR(S):	Kania, Robert Steven, San Diego, CA, United States Bender, Steven Lee, Oceanside, CA, United States Borchardt, Allen J., San Diego, CA, United States Cripps, Stephan James, San Diego, CA, United States Palmer, Cynthia Louise, San Diego, CA, United States Tempczyk-Russell, Anna Maria, Ramona, CA, United States Varney, Michael David, Solana Beach, CA, United States Collins, Michael Raymond, San Diego, CA, United States
PATENT ASSIGNEE(S):	Agouron Pharamaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6531491	B1	20030311
APPLICATION INFO.:	US 2001-983786		20011025 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-609335, filed on 30 Jun 2000, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-142130P	19990702 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Davis, Zinna Northington
LEGAL REPRESENTATIVE:	Richardson, Peter, Zielinski, Bryan C., Reidy, Joseph F.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	8878

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states

associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **319468-45-6P 319468-46-7P**
(prepn. of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)
RN 319468-45-6 USPATFULL
CN Benzamide, 2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 319468-46-7 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L19 ANSWER 52 OF 64 USPATFULL on STN
ACCESSION NUMBER: 2002:192157 USPATFULL
TITLE: Indazole derivatives as JNK inhibitors and compositions and methods related thereto
INVENTOR(S): Bhagwat, Shripad S., San Diego, CA, UNITED STATES
Satoh, Yoshitaka, San Diego, CA, UNITED STATES
Sakata, Steven T., San Diego, CA, UNITED STATES
Buhr, Chris A., Redwood City, CA, UNITED STATES

Albers, Ronald, La Jolla, CA, UNITED STATES
Sapienza, John, Chula Vista, CA, UNITED STATES
Plantevin, Veronique, San Diego, CA, UNITED STATES
Chao, Qi, San Diego, CA, UNITED STATES
Sahasrabudhe, Kiran, San Diego, CA, UNITED STATES
Ferri, Rachel, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103229	A1	20020801
APPLICATION INFO.:	US 2001-910950	A1	20010723 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-221799P	20000731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
LINE COUNT: 12639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: ##STR1##

wherein R.sub.1, R.sub.2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **395107-61-6P**, N-(5,6,7,8-Tetrahydronaphthyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]benzamide
(prepn. of indazole derivs. as JNK enzyme inhibitors)

RN 395107-61-6 USPATFULL

CN Benzamide, N-(5,6,7,8-tetrahydro-1-naphthalenyl)-3-[5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 53 OF 64 USPATFULL on STN

ACCESSION NUMBER:	2002:192132 USPATFULL
TITLE:	Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
INVENTOR(S):	Bender, Steven Lee, Oceanside, CA, UNITED STATES Bhumralkar, Dilip, San Diego, CA, UNITED STATES Collins, Michael Raymond, San Diego, CA, UNITED STATES Cripps, Stephen James, San Diego, CA, UNITED STATES

Deal, Judith Gail, Wildomar, CA, UNITED STATES
Jia, Lei, San Diego, CA, UNITED STATES
Nambu, Mitchell David, San Diego, CA, UNITED STATES
Palmer, Cynthia Louise, La Mesa, CA, UNITED STATES
Peng, Zhengwei, San Diego, CA, UNITED STATES
Varney, Michael David, Solana Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103203	A1	20020801
	US 6635641	B2	20031021
APPLICATION INFO.:	US 2001-764306	A1	20010119 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-177059P	20000121 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Shanks & Herbert, TransPotomac Plaza, Suite 306, 1033 N. Fairfax Street, Alexandria, VA, 22314
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 6933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **351317-89-0P 351318-14-4P 351318-72-4P 351318-82-6P 351319-54-5P 351319-92-1P 351320-69-9P**
(synthesis of heteroarylbenzamides used for inhibiting protein kinases)

RN 351317-89-0 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]- (9CI) (CA INDEX NAME)



RN 351318-14-4 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(pyrazinylthio)methyl]- (9CI)

(CA INDEX NAME)



RN 351318-72-4 USPATFULL
CN Benzamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(1H-1,2,4-triazol-3-ylthio)methyl]- (9CI) (CA INDEX NAME)



RN 351318-82-6 USPATFULL
CN Benzamide, 3-[[(5-amino-1H-1,2,4-triazol-3-yl)thio]methyl]-N-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)



RN 351319-54-5 USPATFULL
CN Benzamide, 3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 351319-92-1 USPATFULL

CN Benzamide, 3-[(pyrazinylthio)methyl]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)-
(9CI) (CA INDEX NAME)



RN 351320-69-9 USPATFULL
CN Benzamide, 3-(4-isoquinolinylmethoxy)-N-(5,6,7,8-tetrahydro-5,5,8,8-
tetramethyl-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L19 ANSWER 54 OF 64 USPATFULL on STN
ACCESSION NUMBER: 2002:113065 USPATFULL
TITLE: Naphthalene derivatives
INVENTOR(S): Chenard, Bertrand L., Waterford, CT, UNITED STATES
Macor, John E., Penfield, NY, UNITED STATES
Segelstein, Barbara E., Gales Ferry, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058811	A1	20020516
APPLICATION INFO.:	US 2001-4990	A1	20011203 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-758074, filed on 10 Jan 2001, PENDING Continuation of Ser. No. US 1995-522349, filed on 15 Sep 1995, ABANDONED A 371 of International Ser. No. WO 1994-US1206, filed on 15 Feb 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-32042, filed on 16 Mar 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul H. Ginsburg, Pfizer Inc, 5th Floor, 150 East 42nd

Street, New York, NY, 10017-5755
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 3210
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (1) where R.sub.1 is of formulae (II), (III), or (IV), or (V); R.sub.2 is --R.sub.4, --O--R.sub.4, --O--S(O).sub.2--R.sub.4, --NR.sub.4R.sub.5, R.sub.4--(CH.sub.2).sub.b--NH(C.dbd.X)--(CH.sub.2).sub.c--, R.sub.4--(CH.sub.2).sub.b--O(C--O)NH--(CH.sub.2).sub.c--(C.dbd.O)NH--, R.sub.4--(C.dbd.O)NH--(C.dbd.O)NH--, --(CH.sub.2).sub.b--NH(C.dbd.X)--(CH.sub.2).sub.c--R.sub.4, R.sub.4--(CH.sub.2).sub.b--O(C.dbd.O)CH.sub.2).sub.c--, --(CH.sub.2).sub.b--O(C.dbd.O)--(CH.sub.2).sub.c--R.sub.4, --NH(C.dbd.X)NH--R.sub.4, R.sub.4--O(C.dbd.O)O--, --O(C.dbd.O)NH--R.sub.4, R.sub.4--O(C.dbd.O)NH--, --(CH.sub.2).sub.b--(C.dbd.O)--(CH.sub.2).sub.c--R.sub.4, --NH--S(O).sub.2--R.sub.4, --C(OH)R.sub.4R.sub.5, --CH(OH)--R.sub.4, --(C.dbd.O)--NR.sub.4, --CN, --NO.sub.2, substituted C.sub.1 to C.sub.6 alkyl, substituted or unsubstituted C.sub.1 to C.sub.6 alkenyl, or substituted or unsubstituted C.sub.1 to C.sub.6 alkynyl, said substituted moieties substituted with a moiety of the formulae --R.sub.4, --R.sub.4R.sub.5, --O--R.sub.4, or --S(O).sub.d--R.sub.4; R.sub.3 is hydrogen, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkylaryl, or aryl; R.sub.4 and R.sub.5 are each independently (XV), (XVI), (XVII), (XVII) hydrogen, --CF.sub.3, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkylaryl, with the proviso that when R.sub.2 is --R.sub.4 or --OR.sub.4, R.sub.4 is not hydrogen or C.sub.1 to C.sub.6 alkyl. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **163498-81-5P**
(prepn. of heterocyclylnaphthalene derivs. as serotonin 5-HT1 agonists and antagonists)
RN 163498-81-5 USPATFULL
CN Benzamide, N-[5,6,7,8-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **163465-77-8P**
(prepn. of heterocyclylnaphthalene derivs. as serotonin 5-HT1 agonists and antagonists)
RN 163465-77-8 USPATFULL
CN Benzamide, N-[5,6-dihydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 55 OF 64 USPATFULL on STN
ACCESSION NUMBER: 2001:95497 USPATFULL
TITLE: Pyrazinyl-substituted naphthalene derivatives
INVENTOR(S): Chenard, Bertrand L., Waterford, CT, United States
Macor, John E., Penfield, NY, United States
Segelstein, Barbara E., Gales Ferry, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001004669	A1	20010621
APPLICATION INFO.:	US 2001-758074	A1	20010110 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-522349, filed on 15 Sep 1995, ABANDONED A 371 of International Ser. No. WO 1994-US1206, filed on 15 Feb 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-32042, filed on 16 Mar 1993, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Paul H. Ginsburg, Pfizer Inc., 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 3213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1##

where

R.sub.1 is of the formulae ##STR2##

R.sub.2 is --R.sub.4, --O--R.sub.4, --O--S (O).sub.2--R.sub.4, --NR.sub.4R.sub.5, R.sub.4--(CH.sub.2).sub.b--NH(C.dbd.X)--(CH.sub.2)--, R.sub.4--(CH.sub.2).sub.b--O(C.dbd.O)NH--(CH.sub.2).sub.c--(C.dbd.O)NH--, R.sub.4(C.dbd.O)NH--(C.dbd.O)NH--, --(CH.sub.2).sub.b--NH(C.dbd.X)--(CH.sub.2).sub.c--R.sub.4, R.sub.4--(CH.sub.2).sub.b--O(C.dbd.)--(CH.sub.2).sub.c--, --(CH.sub.2).sub.b--O(C.dbd.O)--(CH.sub.2).sub.c--R.sub.4, --NH(C.dbd.X)NH--R.sub.4, R.sub.4--O(C.dbd.O)O--, --O(C.dbd.)NH--R.sub.4, R.sub.4--O(C.dbd.O)NH--, --(CH.sub.2).sub.b--(C.dbd.O)--(CH.sub.2).sub.c--R.sub.4, --NH--S(O).sub.2--R.sub.4, --C(OH)R.sub.4R.sub.5, --CH(OH)--R.sub.4, --(C.dbd.O)--NR.sub.4R.sub.5, --CN, --NO.sub.2, substituted C.sub.1 to C.sub.6 alkyl, substituted or unsubstituted C.sub.1 to C.sub.6 alkenyl, or substituted or unsubstituted C.sub.1 to C.sub.6 alkynyl, said substituted moieties substituted with a moiety of the formulae --R.sub.4, --R.sub.4R.sub.5, --O--R.sub.4, or --S(O).sub.d--R.sub.4. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists and may be used in the treatment of depression, anxiety,

eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **163498-81-5P**
(prepn. of heterocyclylnaphthalene derivs. as serotonin 5-HT1 agonists and antagonists)
RN 163498-81-5 USPATFULL
CN Benzamide, N-[5,6,7,8-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **163465-77-8P**
(prepn. of heterocyclylnaphthalene derivs. as serotonin 5-HT1 agonists and antagonists)
RN 163465-77-8 USPATFULL
CN Benzamide, N-[5,6-dihydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 56 OF 64 USPATFULL on STN
ACCESSION NUMBER: 2001:235260 USPATFULL
TITLE: Potassium channel inhibitors
INVENTOR(S): Gross, Michael F., Durham, NC, United States
Castle, Neil A., Cary, NC, United States
PATENT ASSIGNEE(S): ICAgen, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6333337	B1	20011225
APPLICATION INFO.:	US 1999-229315		19990113 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72719P	19980127 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: O'Sullivan, Peter
LEGAL REPRESENTATIVE: Banner & Witcoff, Ltd.
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 2200
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds useful as potassium channel inhibitors and especially useful for the treatment of cardiac arrhythmias and cell proliferative disorders are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **232265-96-2P**
(prepn. of N-(aminotetrahydronaphthyl)arylsulfonamides and analogs as potassium channel blockers)
RN 232265-96-2 USPATFULL
CN Benzamide, N-[8-[[(4-ethylphenyl)sulfonyl](3-pyridinylmethyl)amino]-5,6,7,8-tetrahydro-7-hydroxy-2-naphthalenyl]-3-methoxy- (9CI) (CA INDEX NAME)



L19 ANSWER 57 OF 64 USPATFULL on STN
ACCESSION NUMBER: 2001:55970 USPATFULL
TITLE: 4-Aryl-1-(indanmethyl, dihydrobenzofuranmethyl or dihydrobenzothiophene-methyl) piperazines
INVENTOR(S): Perregaard, Jens Kristian, Jaegerspris, Denmark
Stenberg, John Willie, Copenhagen, Denmark
Hansen, Bitten, Koge, Denmark
PATENT ASSIGNEE(S): H. Lundbeck A/S, Copenhagen-Valby, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6218394	B1	20010417
APPLICATION INFO.:	US 1996-999868		19961209 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1995-DK230, filed on 8 Jun 1995

	NUMBER	DATE

PRIORITY INFORMATION: DK 1994-649 19940608
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ford, John M.
LEGAL REPRESENTATIVE: Darby & Darby
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1524
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 4-Aryl-1-(indanmethyl, dihydrobenzofuramethyl or dihydrobenzothiophenemethyl) piperidine, -tetrahydropyridine or -piperazine compounds of general formula (I) ##STR1##

wherein one of X and Y is CH.sub.2, and the other one is CH.sub.2, O or S; Z is N, C, CH or COH; Ar is an optionally substituted aryl group; R.sup.1 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, acyl, thioacyl, alkylsulfonyl, trifluoromethylsulfonyl, arylsulfonyl, a group R.sup.9 VCO-- where V is O or S and R.sup.9 is alkyl or aryl, or a group R.sup.10 R.sup.11 NCO-- or R.sup.10 R.sup.11 NCS-- wherein R.sup.10 and R.sup.11 are hydrogen, alkyl or aryl, or R.sup.10 and R.sup.11 are linked to form a ring; R.sup.2 is hydrogen, alkyl, cycloalkyl or cycloalkylalkyl; or R.sup.1 and R.sup.2 are linked to form a ring; R.sup.3 -R.sup.5 are hydrogen, halogen, alkyl, alkylcarbonyl, phenylcarbonyl, alkoxy, alkylthio, hydroxy, alkylsulfonyl, cyano, trifluoromethyl, cycloalkyl, cycloalkylalkyl or nitro; R.sup.6 and R.sup.7 are hydrogen or alkyl or they are linked to constitute a 3-7-membered ring; R.sup.8 is hydrogen or alkyl; have effects at central serotonergic receptors and are therefore useful in the treatment of certain psychic and neurologic disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **174776-05-7P 174776-06-8P**
(prepn. of N-(indanylmethyl)piperidines and -piperazines and analogs as 5-HT1A and/or 5-HT2A ligands)
RN 174776-05-7 USPATFULL
CN Cyclopropanecarboxamide, N-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]-2,3-dihydro-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



RN 174776-06-8 USPATFULL
CN Cyclopentanecarboxamide, N-[3-[[4-(4-fluorophenyl)-1-piperidinyl]methyl]-2,3-dihydro-1H-inden-5-yl]- (9CI) (CA INDEX NAME)



L19 ANSWER 58 OF 64 USPATFULL on STN
ACCESSION NUMBER: 1998:17308 USPATFULL
TITLE: Amidine derivatives and platelet aggregation inhibitor containing the same
INVENTOR(S): Yamashita, Hiroyuki, Chiba-ken, Japan
Okumura, Kunio, Chiba-ken, Japan

Shimazaki, Toshiyuki, Chiba-ken, Japan
Kanematsu, Akihito, Aichi-ken, Japan
Aoki, Yoji, Chiba-ken, Japan
Nakajima, Yuki, Chiba-ken, Japan
Yazawa, Kouhei, Chiba-ken, Japan
Kibayashi, Kenji, Chiba-ken, Japan
PATENT ASSIGNEE(S): Mitsui Toatsu Chemicals, Inc., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5719145		19980217
APPLICATION INFO.:	US 1996-699346		19960819 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Kifle, Bruce
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 2642
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a substituted amidine derivative which has an excellent platelet aggregation inhibiting action on the basis of fibrinogen antagonism and is particularly excellent in effectiveness on oral administration, and the platelet aggregation inhibitor containing the substituted amidine derivative of the invention as an effective ingredient is effective for prevention and treatment of thrombosis, and restenosis or reocclusion after percutaneous transluminal coronary angioplasty or percutaneous transluminal coronary recanalization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **188349-90-8P 188349-91-9P 188350-01-8P 188350-02-9P 188350-03-0P 188350-04-1P 188350-06-3P 188350-07-4P 188350-10-9P 188350-11-0P 188350-27-8P 188350-28-9P 188350-30-3P 188350-33-6P 188350-34-7P 188350-36-9P 188350-38-1P 188350-44-9P 188350-46-1P**
(prepn. of amidine derivs. as platelet aggregation inhibitors)
RN 188349-90-8 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 188349-91-9 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-01-8 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-thiomorpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-02-9 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-thiomorpholinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-03-0 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-04-1 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-06-3 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-1-piperidinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-07-4 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-1-piperidinylmethyl)benzoyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-10-9 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-1-pyrrolidinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-11-0 USPATFULL
CN 2-Naphthaleneacetic acid, 7-[[4-[(hexahydro-1H-azepin-1-yl)iminomethyl]benzoyl]amino]-1,2,3,4-tetrahydro-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 188350-27-8 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(2-pyridinylmethyl)amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-28-9 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(2-pyridinylmethyl)amino]methyl]benzoyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-30-3 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(3-pyridinylmethyl)amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-33-6 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[(4-pyridinylmethyl)amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-34-7 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[[2-(4-pyridinyl)ethyl]amino]methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-36-9 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino(4-phenyl-1-piperazinyl)methyl]benzoyl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 188350-38-1 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-[imino[4-(2-pyridinyl)-1-piperazinyl]methyl]benzoyl]amino]-, ethyl ester, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 188350-44-9 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, ethyl ester, monohydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



● HCl

RN 188350-46-1 USPATFULL
CN 2-Naphthaleneacetic acid, 1,2,3,4-tetrahydro-7-[[4-(imino-4-morpholinylmethyl)benzoyl]amino]-, monohydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



HCl

L19 ANSWER 59 OF 64 USPATFULL on STN
ACCESSION NUMBER: 97:7930 USPATFULL
TITLE: Compositions containing sertraline and a 5-HT.sub.1D

receptor agonist or antagonist

INVENTOR(S): Howard, Harry R., New York, NY, United States
Macor, John E., New York, NY, United States
Chenard, Bertrand L., New York, NY, United States
Sprouse, Jeffrey S., New York, NY, United States
Schulz, David W., New York, NY, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5597826		19970128
APPLICATION INFO.:	US 1994-306230		19940914 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Acquah, Samuel A.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Butterfield, Garth
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 3659

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **163465-77-8P**
(prepn. of piperazinylnaphthalene derivs. as central nervous system agent for use in combination with sertraline)

RN 163465-77-8 USPATFULL

CN Benzamide, N-[5,6-dihydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **163498-81-5P**
(prepn. of piperazinylnaphthalene derivs. as central nervous system agent for use in combination with sertraline)
RN 163498-81-5 USPATFULL
CN Benzamide, N-[5,6,7,8-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 60 OF 64 USPATFULL on STN

ACCESSION NUMBER:	93:44387 USPATFULL
TITLE:	Aromatic carboxamides
INVENTOR(S):	Klaus, Michael, Weil/Rhein, Germany, Federal Republic of Mohr, Peter, Basel, Switzerland
PATENT ASSIGNEE(S):	Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5216153		19930601
APPLICATION INFO.:	US 1992-852607		19920317 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-551831, filed on 12 Jul 1990, now patented, Pat. No. US 5128470		

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1989-2818	19890728

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Gerstl, Robert
LEGAL REPRESENTATIVE:	Gould, George M., Epstein, William H., Pokras, Bruce A.
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1
LINE COUNT:	552

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the general formula ##STR1## wherein R.sup.1 is hydrogen, halogen or OR.sup.5 ; R.sup.2 is hydrogen, lower-alkyl lower-alkoxy or halogen; R.sup.3 and R.sup.4 each independently are lower-alkyl or taken together are alkylene with 3-5 C atoms in a straight-chain; R.sup.5 is hydrogen, acyl, lower-alkoxycarbonyl, lower-alkyl, amino-lower-alkyl, mono-alkylamino-lower-alkyl di-alkylamino-lower-alkyl or a N-containing 5-8-membered saturated or unsaturated monocyclic heterocyclic ring which is attached via a N atom to lower alkyl; and M signifies --CONH-- or --NHCO--, which can be used as medicaments, e.g., for the treatment of neoplasms and dermatological indications of an inflammatory and allergic nature.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **134599-37-4P 134599-40-9P**
(prepn. of, as anticancer and dermatol. agent)
RN 134599-37-4 USPATFULL
CN Benzamide, 4-[2-(4-morpholinyl)ethoxy]-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 134599-40-9 USPATFULL
CN Benzamide, N-(2,3-dihydro-1,1,3,3-tetramethyl-1H-inden-5-yl)-4-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



L19 ANSWER 61 OF 64 USPATFULL on STN

ACCESSION NUMBER:	92:55631 USPATFULL
TITLE:	Aromatic carboxamides
INVENTOR(S):	Klaus, Michael, Weil am Rhein, Germany, Federal Republic of Mohr, Peter, Basel, Switzerland
PATENT ASSIGNEE(S):	Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5128470		19920707	
APPLICATION INFO.:	US 1990-551831		19900712	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1989-2818	19890728

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted

PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Gould, George M., Epstein, William H., Pokras, Bruce A.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 589
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the general formula ##STR1## wherein R.sup.1 is hydrogen, halogen or OR.sup.5 ; R.sup.2 is hydrogen, lower-alkyl, lower-alkoxy or halogen; R.sup.3 and R.sup.4 each independently are lower-alkyl or taken together are alkylene with 3-5 C atoms in a straight-chain; R.sup.5 is hydrogen, acyl, lower-alkoxycarbonyl, lower-alkyl, amino-lower-alkyl, mono-alkylamino-lower-alkyl, di-alkylamino-lower-alkyl or a N-containing 5-8-membered saturated or unsaturated monocyclic heterocyclic ring which is attached via a N atom to lower alkyl; and M signifies --CONH-- or --NHCO--, which can be used as medicaments, e.g., for the treatment of neoplasms and dermatological indications of an inflammatory and allergic nature.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **134599-37-4P 134599-40-9P**
(prepn. of, as anticancer and dermatol. agent)
RN 134599-37-4 USPATFULL
CN Benzamide, 4-[2-(4-morpholinyl)ethoxy]-N-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 134599-40-9 USPATFULL
CN Benzamide, N-(2,3-dihydro-1,1,3,3-tetramethyl-1H-inden-5-yl)-4-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



L19 ANSWER 62 OF 64 USPATFULL on STN
ACCESSION NUMBER: 91:106087 USPATFULL
TITLE: Radioiodinated benzovesamicol analogs for cholinergic nerve mapping
INVENTOR(S): Wieland, Donald M., Ann Arbor, MI, United States
Jung, Yong-Woon, Ann Arbor, MI, United States
Van Dort, Marcian E., Ann Arbor, MI, United States
Gildersleeve, David L., Ann Arbor, MI, United States
PATENT ASSIGNEE(S): The University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

NUMBER	KIND	DATE

PATENT INFORMATION: US 5077035 19911231
APPLICATION INFO.: US 1990-523233 19900514 (7)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Maples, John S.
LEGAL REPRESENTATIVE: Rohm & Monsanto
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 701
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Radioiodinated benzovesamicol analogs which selectively localize in presynaptic cholinergic neurons of the general formula: ##STR1## where X is selected from the group consisting of H, OH, NH.sub.2, NHCO-3-[I]-Ph, and a radioactive isotope of iodine, and Y is selected from the group of H and a radioactive isotope of iodine, Y being H is X contains iodine. Illustrative examples include: (.+-.)-trans-2-hydroxy-5-iodo-3-(4-phenylpiperidino)tetralin; (.+-.)-trans-3-hydroxy-5-iodo-2-(4-phenylpiperidino)tetralin; (.+-.)-trans-5-amino-2-hydroxy-8-iodo-3-(4-phenylpiperidino)tetralin; and (.+-.)-trans-2-hydroxy-5-(3-iodobenzamido)-3-(4-phenylpiperidino)tetralin. The novel radioiodinated benzovesamicol analogs may be used as radiopharmaceuticals to visualize cholinergic neurons with conventional imaging devices which are typically found in most nuclear medicine or radiology clinics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **139399-87-4D**, radioiodine-labeled **139399-88-5D**, radioiodine-labeled **139399-89-6D**, radioiodine-labeled
(brain imaging with cholinergic neuron-selective)
RN 139399-87-4 USPATFULL
CN Benzamide, 2-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139399-88-5 USPATFULL
CN Benzamide, 3-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 139399-89-6 USPATFULL
CN Benzamide, 4-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **139399-88-5P**
(prepn. of, for brain imaging agent prepn.)
RN 139399-88-5 USPATFULL
CN Benzamide, 3-iodo-N-[5,6,7,8-tetrahydro-6-hydroxy-7-(4-phenyl-1-piperidinyl)-1-naphthalenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L19 ANSWER 63 OF 64 USPATFULL on STN
ACCESSION NUMBER: 86:15612 USPATFULL
TITLE: Oxoindolizine and oxoindolizinium compounds useful as dyes
INVENTOR(S): Fletcher, Jr., George L., Pittsford, NY, United States
Bender, Steven L., Pasadena, CA, United States
Wadsworth, Donald H., Rochester, NY, United States
PATENT ASSIGNEE(S): Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:	US 4577024	19860318
APPLICATION INFO.:	US 1982-412444	19820827 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1981-278022, filed on 29 Jun 1981, now abandoned	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Jiles, Henry R.	
ASSISTANT EXAMINER:	Dentz, Bernard I.	
LEGAL REPRESENTATIVE:	Knapp, Richard E.	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1,2	
LINE COUNT:	1398	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Oxoindolizine and oxoindolizinium dyes are novel compounds useful in imaging, such as laser recording and reading. These dyes are formed by (1) the reaction of a cyclopropenone and a pyridine compound, (2) by reaction of (a) color-forming couplers with (b) reaction products from the reaction of cyclopropenones with pyridine compounds, or (3) by condensation reactions of indolizinols, indolizinones, and indolizinium ions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **86222-18-6 86222-19-7 86222-20-0**
(dye, optical absorption max. of)

RN 86222-18-6 USPATFULL

CN 2-Naphthalenecarboxamide, N-[1-[4-[(4-chlorobenzoyl)amino]phenyl]-2,3-dihydro-1,3,3-trimethyl-1H-inden-5-yl]-1,4-dihydro-1-oxo-4-(1-oxo-2,3-diphenyl-7(1H)-indolizinylidene)- (9CI) (CA INDEX NAME)



RN 86222-19-7 USPATFULL

CN 2-Naphthalenecarboxamide, N-[1-[4-[(4-bromobenzoyl)amino]phenyl]-2,3-dihydro-1,3,3-trimethyl-1H-inden-5-yl]-1,4-dihydro-1-oxo-4-(1-oxo-2,3-diphenyl-7(1H)-indolizinylidene)- (9CI) (CA INDEX NAME)



RN 86222-20-0 USPATFULL
CN 2-Naphthalenecarboxamide, N-[1-[4-[(2-chlorobenzoyl)amino]phenyl]-2,3-dihydro-1,3,3-trimethyl-1H-inden-5-yl]-1,4-dihydro-1-oxo-4-(1-oxo-2,3-diphenyl-7(1H)-indolizinylidene)- (9CI) (CA INDEX NAME)



L19 ANSWER 64 OF 64 USPATFULL on STN

ACCESSION NUMBER:	79:19049 USPATFULL
TITLE:	Color diffusion transfer photographic elements
INVENTOR(S):	Deguchi, Hidetaka, Tama, Japan Takahashi, Jiro, Hachioji, Japan Kunieda, Naoshi, Tokyo, Japan
PATENT ASSIGNEE(S):	Konishiroku Photo Industry Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4149892		19790417	
APPLICATION INFO.:	US 1977-810910		19770629	(5)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1976-78057	19760701

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Schilling, Richard L.
LEGAL REPRESENTATIVE:	Bierman & Bierman
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1

LINE COUNT: 1102
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel color diffusion transfer photographic element is disclosed which is characterized as having a photosensitive element containing a compound represented by the formula ##STR1## wherein A represents oxygen or a group of the formula .dbd.NR (in which R represents hydroxyl or an amino group); X represents hydrogen or halogen; Z represents a group of nonmetallic atoms necessary to form a first ring and being a 5 to 7-membered nonaromatic hydrocarbon ring which may be fused with a second ring, at least one of said first ring and said second ring having one or more substituents wherein at least one of said substituents is a ballast group which renders said compound nondiffusible during processing with said solution; J represents a divalent group; D represents a dye moiety or a dye precursor moiety; and n represents zero or 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **66518-40-9P**
(prepn. of)
RN 66518-40-9 USPATFULL
CN Benzamide, N-[2-[[[4-[[[4-[(3-bromo-4-hydroxyphenyl)amino]-4,5-dihydro-1-methyl-5-oxo-1H-pyrazol-3-yl]amino]carbonyl]phenyl]sulfonyl]amino]-2,3-dihydro-1-oxo-1H-inden-4-yl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

FILE 'CAOLD' ENTERED AT 10:38:46 ON 16 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L1             STR
L3         650 SEA FILE=REGISTRY SSS FUL L1
L12            STR
L15        238 SEA FILE=REGISTRY SUB=L3 SSS FUL L12
L18          1 SEA FILE=CAOLD ABB=ON  L15
```

```
=> d iall hitstr l18
```

L18 ANSWER 1 OF 1 CAOLD COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: CA65:839h CAOLD
TITLE: dyes (acid anthraquinone)
PATENT ASSIGNEE: Geigy, J. R., A.-G.
DOCUMENT TYPE: Patent

	PATENT NO.	KIND	DATE
PI	NL 6510003		
	BE 667809		
	FR 1442062		
	GB 1047106		

INDEX TERM: 625-51-4 6396-89-0 6396-90-3 6431-66-9 107631-42-5
107744-29-6
IT **107744-29-6**
RN 107744-29-6 CAOLD
CN 4',4'''-Bi[5-indancarbox-o-anisidide], 2,2''-bis(3-hydroxy-6,8-dimethyl-2(1H)-quinolylidene)-1,1'',3,3''-tetraoxo- (7CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



=> fil hom
FILE 'HOME' ENTERED AT 10:39:01 ON 16 JAN 2004

Vat dyes. CIBA Ltd. (by Max Staeuble and Kurt Weber). Swiss. 397,120 (Cl. C 09*b*), Feb. 15, 1966, Appl. Dec. 31, 1958; 3 pp. Vat dyes contg. ≥1 $ClCH_2CH_2NHSO_2$ group and useful for dyeing cellulose fibers were prepd. Thus, a mixt. of I (R = $SO_2NHCH_2CH_2OH$) 12.7, $PhNO_2$ 120, $SOCl_2$ 7.2, and $HCONMe_2$



(I)



(II)

1 part was stirred at 120–5° for 16 hrs., cooled, the ppt. filtered, washed with $PhNO_2$ and H_2O, and dried in vacuo to give I (R = $SO_2NHCH_2CH_2Cl$), which dyed cotton fast golden yellow shades. Similarly II (X = Cl) and II (X = 3-$ClCH_2CH_2NHSO_2C_6H_4NH$), yellow on cotton, were prepd. Roland Bamberger

Metallized anthraquinone dyes. Allied Chemical Corp. Brit. 1,024,394 (Cl. C 09*b*), March 30, 1966; U.S. Appl. April 26, 1963; 5 pp. Cu and Ni complexes of I give level dyeings of excellent fastness on synthetic polyamide fibers. Thus, con-



(I)

densation of 33 parts 1-methylamino-4-bromoanthraquinone and 2 parts 2,5-$HO(H_2N)C_6H_3CO_2H$ in boiling BuOH in the presence of KOAc, HOAc and Cu bronze gave I (X = Me, Y = H) (II). Metallization in aq. soln. at 90–5° with $NiCl_2.6H_2O$ gave a product contg. 6% Ni which dyed nylon bright greenish-blue shades. A similar product contg. 5.2% Ni gave similar dyeings. Also prepd. are the Cu complex of II (greenish blue) and the Ni complex of I (X = H, Y = Br) (steel gray).

Arnold T. Peters

3-Hydroxyquinophthalone pigments. CIBA Ltd. Belg. 665,978, Dec. 27, 1965; Swiss. Appl. June 26, 1964; 24 pp. Compds. of the general formula I, where *A* and R are arylene



(I)



(II)

residues, are yellow pigments for coloring plastics, resins, and lacquers. Thus, 7.03 parts II ($R^1 = R^2 = H$), prepd. by heating trimellitic anhydride with 2-methyl-3-hydroxy-4-quinolinecarboxylic acid and treating the product with $SOCl_2$ (*CA* 57, 3420*h*), was heated with 250 parts *o*-$C_6H_4Cl_2$ at 100–10°, then 1.08 parts *p*-$C_6H_4(NH_2)_2$ (III) in 50 parts *o*-$C_6H_4Cl_2$ at 100–10° and 0.1 part pyridine added, the mixt. heated for 5–6 hrs. at 140–60°, cooled to 100°, the ppt. filtered, washed with *o*-$C_6H_4Cl_2$ at 100–20° to a colorless filtrate, then washed with MeOH and with H_2O, and vacuum-dried to a yellow-orange powder, which, finely divided and laminated with poly(vinyl chloride), gave a yellow film. Similarly, other I were prepd. from II (R^1, R^2, and diamine given): Br, Br, (4-$H_2NC_6H_4)_2$ (IV); Cl, Cl, IV; Cl, H, III;



(V)



(VI)

Br, H, III; Cl, Me, III; Me, Me, [4,3-$H_2N(MeO)C_6H_3]_2$. In addn., other I were prepd. from V and III, and from VI and 2,5-1,4-$Cl_2C_6H_2(NH_2)_2$. Irving T. Beach

Acid anthraquinone dye. J. R. Geigy A.-G. Neth. Appl. 6,510,003 (Cl. C 09*b*), Feb. 4, 1966; Swiss. Appl. Aug. 3, 1964; 16 pp. I was prepd. by several methods. 1-Cyclohexylamino-4-[*p*-(*p*-tolyloxy)anilino]anthraquinone (II) (50.2 g.) added at 23–5° to 500 g. $H_2SO_4.H_2O$, kept 18 hrs. at 23–5°, treated 24 hrs. with 10.25 g. $AcNHCH_2OH$ (III), and poured onto 1200 g. ice and 120 g. NaCl, and the ppt. dissolved in 400 cc. H_2O, ad-



(I)

justed with dil. aq. NaOH to pH 7, and salted at 60° with 35 g. NaCl yielded I, dark powder, greenish blue in H_2O; it dyes wool from a weakly acidic bath greenish blue shades. II (50.2 g.) in 500 g. 90% H_2SO_4 treated with stirring at 0–5° with 10.52 g. III, stirred 24 hrs. at 5–10°, and poured onto 1200 g. ice, and the product treated 4 hrs. at 18–20° with 500 g. 5% oleum yielded I.

b A similar dye was obtained using 21.04 g. III. MeCN (6.4 g.) in 65 g. 93% H_2SO_4 stirred 3 hrs. at 33–5°, cooled to 10–12°, treated during 1 hr. with 7.5 g. $(ClCH_2)_2O$, stirred 3 hrs. at 10–12° and 4 hrs. at 13–15°, added to 50.2 g. I in 500 g. $H_2SO_4.H_2O$ (stirred previously 18 hrs. at 23–5°), stirred 24 hrs. at 23–5°, and poured onto 1200 g. ice and 120 g. NaCl yielded I. An example for the dyeing of wool flannel with I is given.

F. W. Hoffmann

Sensitized photographic emulsions. Agfa A.-G. (by Johannes Goetze and Helmut Kampfer). Belg. 654,816, April 26, 1965; Ger. Appl. Oct. 26, 1963; 21 pp. I and compds. of the general

c formula II are prepd.; emulsions contg. 10–60 mg. merocyanine/kg. are prepd. Thus, a mixt. of 6.7 g. III [R = $CH_2CH(OAc)$-



(I)



(II)

d $CH_2SO_3^-$, R^1 = CH:CHN(Ac)Ph], 5.2 g. 1-phenyl-3-methyl-



(III)

thiohydantoin, 125 ml. EtOH, and 10 ml. Et_3N is heated 50 min. to give II [R = Me, X = NPh, Y = O, R^1 = H], m. 375° (MeOH–iso-PrOH), sensitization max. 530 mμ. Similarly prepd. are I, m. 385°, sensitization max. 495 mμ, and the following II (R, X, Y, R^1, m.p., $\lambda_{max.}$ in mμ, and sensitization max. in mμ given): Et, NPh, O, H, >360°, 480 (MeOH), 535; Et, S, O, H,

e 375°, —, 560; Me, NPh, O, Me, —, —, 535; Ph, NMe, O, H, 381°, —, 530; Et, O, O, H, 285° (MeOH–iso-PrOH), —, 520. A mixt. of 2.9 g. III [R = $CH_3CH(OH)CH_2SO_3^-$, R^1 = Me, Y = S], 2.6 g. 3-ethylthiazolidine-2-thione-4-one, 30 ml. Ac_2O, 5 ml. Et_3N is refluxed 1 hr. to give II (R = Et, X = Y = S, R^1 = H), m. 342° (MeOH–iso-PrOH), $\lambda_{max.}$ 525 mμ, sensitization max. 590 mμ. II [R = Et, X = NPh, Y = O, R^1 = H] (30 mg.) is added to a Ag(Cl, Br) emulsion, sensitized with $AuCl_3$ and stabilized with phenylmercaptotetrazole, the emulsion is coated on a polyester support, and the element is exposed behind an AGFA

f no. 104 red filter and 5-stage x-ray sensitometer and developed with a compn. (1 l.) prepd. from 1.0 g. *p*-$MeNHC_6H_4OH$, 3.0 g. hydroquinone, 13.0 g. Na_2SO_3, 26.0 g. Na_2CO_3, 1.0 g. KBr, and H_2O to give sensitivity 19, black chamber reliability 2 as compared 18 and 4, resp., for the control. BDPF

Pyrimidine dyes. Jakob Benz and Hans Ischer (to Sandoz Ltd.). U.S. 3,247,194 (Cl. 260–242), April 19, 1966; Swiss Appl. Nov. 6, 1958; 6 pp. Compds. of the general formula $CuPc(n\text{-}SO_3H)_m$ ($n\text{-}SO_2NHC_6H_4OQ\text{-}3)_pR$ (I), where Pc is phthalocyanine, Q is dichloropyrimidinyl, *n* is 3 or 4, *m* is 1.5–3, *p* is 1–1.5, and R is $SO_2NHC_2H_4OH$ or H, are H_2O-sol., turquoise dyes for natural and synthetic fibers. Thus, 57.6 parts

g CuPc was stirred with 300 parts $ClSO_3H$ at 140° for 1 hr., the mixt. cooled to 70–80°, 45 parts $SOCl_2$ slowly added, stirring continued at 75–80° for 2 hrs., the mass poured on ice, the pptd. $CuPc(SO_2Cl)_4$ filtered, and washed with weakly acid ice–H_2O. The residue was stirred into ice-H_2O 500, 3-$H_2NC_6H_4OH$ 11 parts added, the mixt. neutralized with dil. NaOH, 60 parts $NaHCO_3$ added, the mixt. stirred at room temp. for 12 hrs., heated to 70°, after 5 hrs. NaOH added until soln. was complete, the intermediate pptd. with HCl, filtered, and washed with dil. HCl. The residue was stirred into 800 parts H_2O, neutralized with aq. NaOH, 18.5 parts 2,4,6-trichloropyrimidine (II) added at 85–90°, the soln. stirred for 12 hrs. at 85–90°, keeping the pH at 6–7

h with dil. NaOH, 18.5 parts II added, and the mixt. stirred at 85–90° for 12 hrs. to give I (*n* = 3, *m* = 3, *p* = 1, R = H), which dyed viscose rayon turquoise. Similarly, other I were prepd. (*n*, *m*, *p*, and R given): 3, 1.5, 1.5, $SO_2NHC_2H_4OH$; 4, 3, 1, H; 3, 2, 1, H; 3, 3, 1, H (Pc metal-free). Irving T. Beach

CA 66D answer